WO1996007739A2 - Interleukin-1 type 3 receptors - Google Patents

Interleukin-1 type 3 receptors Download PDF

Info

Publication number
WO1996007739A2
WO1996007739A2 PCT/US1995/012037 US9512037W WO9607739A2 WO 1996007739 A2 WO1996007739 A2 WO 1996007739A2 US 9512037 W US9512037 W US 9512037W WO 9607739 A2 WO9607739 A2 WO 9607739A2
Authority
WO
WIPO (PCT)
Prior art keywords
type
receptor
sequence
amino acid
interleukin
Prior art date
Application number
PCT/US1995/012037
Other languages
French (fr)
Other versions
WO1996007739A3 (en
Inventor
Timothy W. Lovenberg
Tilman Oltersdorf
Chen W. Liaw
William Clevenger
Errol B. Desouza
Original Assignee
Neurocrine Biosciences, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences, Incorporated filed Critical Neurocrine Biosciences, Incorporated
Priority to EP95934482A priority Critical patent/EP0779923A2/en
Priority to JP8509726A priority patent/JPH10508743A/en
Priority to AU36805/95A priority patent/AU705595B2/en
Publication of WO1996007739A2 publication Critical patent/WO1996007739A2/en
Publication of WO1996007739A3 publication Critical patent/WO1996007739A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates generally to cell surface receptors, and more specifically, to Interleukin-1 Type 3 receptors.
  • Interleukin- 1 (“IL-1 ”) is a cytokine which is known to be a key mediator of immunological and pathological responses to stress, infection and antigenic challenge (Oppenheim et al., Immunol. Today 7:45-46, 1986; Dinarello, FASEB J. 2: 108-1 15, 1988; and Mizel, FASEB J. 3:2379-2388, 1989).
  • IL-1 is known to have a variety of effects on the brain and central nervous system. For example, IL-1 has been postulated to be involved in the induction of fever (Kluger, Physiol. Rev. 77:93-127, 1991), increased duration of slow wave sleep (Opp et al., Am. J.
  • Type I receptors bind both IL-l ⁇ and IL-l ⁇ , and can be found on T cells, fibroblasts, keratinocytes, endothelial cells, synovial lining cells, chondrocytes and hepatocytes (U.S. Patent Nos.
  • Type II receptors can be found on various B cell lines, including the Raji human B-cell lymphoma line (Bomsztyk et al., PNAS 56:8034-8038, 1989; Horuk et al., J. Biol. Chem. 262:16275-16278, 1987; Horuk and McCubrey, Biochem. J. 260:657-663, 1989).
  • the present invention provides new, previously unidentified Interleukin receptors, designated Interleukin- 1 Type 3 receptors ("IL-I R").
  • IL-I R Interleukin- 1 Type 3 receptors
  • the present invention provides compositions and methods which utilize such receptors, as well as other, related advantages. Summary of the Invention
  • the present invention provides compositions and methods which comprise Interleukin- 1 Type 3 receptors.
  • isolated nucleic acid molecules are provided which encode Interleukin- 1 Type 3 receptors.
  • the isolated nucleic acid molecules comprise the sequence of nucleotides in Sequence I.D. No. 1, from nucleotide number 129 to nucleotide number 1814.
  • the isolated nucleic acid molecules encode a protein having the amino acid sequence of Sequence I.D. No. 2, from amino acid number 1 to amino acid number 562.
  • isolated nucleic acid molecules are provided in Sequence I.D. No. 3, from nucleotide number 89 to nucleotide number 1771.
  • nucleic acid molecules encode a protein having the amino acid sequence of Sequence I.D. No. 4, from amino acid number 1 to amino acid number 561.
  • Nucleic acid molecules which encode IL-1 Type 3 receptors of the present invention may be isolated from virtually any warm-blooded animal, including for example, humans, macaques, horses, cattle, sheep, pigs, dogs, cats, rats and mice.
  • isolated nucleic acid molecules which encode soluble Interleukin- 1 Type 3 receptors.
  • the isolated nucleic acid molecules comprise the sequence of nucleotides in Sequence I.D. No. 1, from nucleotide number 129 to nucleotide number 1136.
  • the isolated nucleic acid molecules encode a protein having the amino acid sequence of Sequence I.D. No. 2, from amino acid number 1 to amino acid number 336.
  • the nucleic acid molecules comprise the sequence of nucleotides in Sequence I.D. No. 3, from nucleotide number 89 to nucleotide number 1102.
  • nucleic acid molecules encode a protein having the amino acid sequence of Sequence I.D. No. 4, from amino acid number 1 to amino acid number 338.
  • nucleic acid molecules which encode soluble IL-1 Type 3 receptors of the present invention may be isolated from virtually any warm-blooded animal, including for example, humans, macaques, horses, cattle, sheep, pigs, dogs, cats, rats and mice.
  • expression vectors are provided which are capable of expressing the above-described nucleic acid molecules.
  • such vectors comprise a promoter operably linked to one of the above-described nucleic acid molecules.
  • recombinant viral vectors are provided which are capable of directing the expression of one of the above described nucleic acid molecules.
  • Representative examples of such viral vectors include retroviral vectors, adenoviral vectors, and he ⁇ es simplex virus vectors.
  • host cells containing one of the above-described recombinant vectors.
  • isolated Interleukin- 1 Type 3 receptors are provided. Within one embodiment, such receptors have the amino acid sequence of Sequence I.D. No. 2, from amino acid number 1 to amino acid number 562. Within another embodiment, the receptors have the sequence of Sequence I.D. No. 4, from amino acid number 1 to amino acid number 561. Within yet further aspects of the invention, isolated soluble Interleukin- 1 Type 3 receptors are provided. Within one embodiment, the isolated soluble Interleukin- 1 Type 3 receptors have the amino acid sequence of Sequence I.D. No. 2, from amino acid number 1 to amino acid number 336. Within another embodiment, the soluble receptors have the sequence of Sequence I.D. No. 4, from amino acid number 1 to amino acid number 338.
  • isolated antibodies capable of specifically binding to an Interleukin- 1 Type 3 receptor are provided.
  • the antibody may be selected from the group consisting of polyclonal antibodies, monoclonal antibodies, and antibody fragments.
  • antibodies are provided which are capable of blocking the binding of IL-1 to an Interleukin- 1 Type 3 receptor.
  • the antibody is selected from the group consisting of murine and human antibodies.
  • the present invention also provides hybridomas which produces an antibody as described above.
  • nucleic acid molecules are provided which are capable of specifically hybridizing to a nucleic acid molecule encoding any of the Interleukin- 1 Type 3 receptors described above.
  • Such molecules may be between at least "y" nucleotides long, wherein "y” is any integer between 14 and 2044, and furthermore, may be selected suitable for use as probes or primers described below.
  • Particularly preferred probes of the present invention are at least 18 nucleotides in length.
  • Figure 1 schematically illustrates a rat IL-1 type 3 receptor.
  • Figure 2 is a table which lists the homology of a human IL-1 type 3 receptor with its rat homologue, and other interleukin receptors.
  • Figure 3 is a graph which shows stimulation of a reporter product via a human IL-1 type 3 receptor.
  • Figure 4 is a graph which shows the expression pattern of the IL-1 Type
  • Figures 5 A and B are two graphs wh ich show inhibition of thymocyte proliferation by soluble IL-1 receptors.z
  • Interleukin- 1 Type 3 Receptors refers to receptor proteins which bind Interleukin- 1 ( ⁇ or ⁇ ), and, when expressed on a cell surface, transduce the signal provided by Interleukin- 1 to the cell, thereby mediating a biological effect within the cell.
  • IL-1 Type 3 receptors exist as membrane bound proteins, consisting of an extracellular domain, transmembrane domain, and intracellular domain (see Figure 1).
  • IL-1-3R may be distinguished from other Interleukin-1 receptors based upon criteria such as affinity of substrate binding, tissue distribution, and sequence homology.
  • IL-1-3R of the present invention should be greater than 50% homologous, preferably greater than 75% to 80% homologous, more preferably greater than 85% to 90% homologous, and most preferably greater than 92%, 95%, or 97% homologous to the IL-1-3R disclosed herein (e.g., Sequence I.D. No. 1).
  • IL1-3R should be understood to include not only the proteins which are disclosed herein, but substantially similar derivatives and analogs as discussed below.
  • Soluble Interleukin- 1 Type 3 Receptor (“sILl-3R”) refers to a protein which has an amino acid sequence corresponding to the extracellular region of an Interleukin- 1 Type 3 receptor.
  • the extracellular region of IL-1-3R may be readily determined by a hydrophobicity analysis utilizing a computer program such as PROTEAN (DNASTAR, Madison, WI), or by an alignment analysis with other known type 1 and type 2 Interleukin- 1 receptors.
  • Nucleic acid molecule refers to a nucleic acid polymer or nucleic acid sequence, which exists in the form of a separate fragment or as a component of a larger nucleic acid construct.
  • the nucleic acid molecule must have been derived from nucleic acids isolated at least once in substantially pure form, (i.e., substantially free of contaminating endogenous materials), and in a quantity or concentration enabling identification and recovery.
  • Such sequences are preferably provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns.
  • nucleic acid molecules should be understood to include deoxyribonucleic acid (“DNA”) molecules (including genomic and cDNA molecules), ribonucleic acid (“RNA”) molecules, hybrid or chimeric nucleic acid molecules (e.g., DNA-RNA hybrids), and where appropriate, nucleic acid molecule analogs and derivatives (e.g., peptide nucleic acids (“PNA”)). Nucleic acid molecules of the present invention may also comprise sequences of non-translated nucleic acids where such additional sequences do not interfere with manipulation or expression of the open reading frame (e.g., sequences which are 5' or 3' from the open reading frame).
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • PNA peptide nucleic acids
  • Recombinant expression vector refers to a replicable nucleic acid construct used either to amplify or to express nucleic acid sequences which encode IL-1 Type 3, or sIL-1 Type 3 receptors. This construct comprises an assembly of (l) a genetic element or elements having a regulatory role in gene expression, for example, promoters, and (2) the structural or coding sequence of interest.
  • the recombinant expression vector may also comprise appropriate transcription and translation initiation and termination sequences.
  • the present invention provides isolated nucleic acid molecules encoding Interleukin- 1 Type 3 receptors.
  • One representative IL-1 Type 3 receptor which may be obtained utilizing the methods described herein (see, e.g., Example 1) is schematically illustrated in Figure 1. Briefly, this IL-1 Type 3 receptor (see Sequence I.D. Nos. 1 and 2) is composed of an Extracellular N-terminal Domain (amino acids 1 - 336), a Transmembrane Domain (amino acids 337 - 357), and a C-terminal Intracellular Domain (358 - 562).
  • IL-1 Type 3 receptor has been provided for pu ⁇ oses of illustration (see also Sequence I.D. Nos. 3 and 4), the present invention should not be so limited.
  • IL-1-3R and sIL-l-3R as utilized herein should be understood to include a wide variety of IL-1 Type 3 receptors which are encoded by nucleic acid molecules that have substantial similarity to the sequences disclosed in Sequences I.D. Nos. 1 and 3.
  • nucleic acid molecules which encode IL-1 Type 3 receptors are deemed to be substantially similar to those disclosed herein if: (a) the nucleic acid sequence is derived from the coding region of a native IL-1 Type 3 receptor gene (including, for example, allelic variations of the sequences disclosed herein); (b) the nucleic acid sequence is capable of hybridization to nucleic acid sequences of the present invention under conditions of either moderate (e.g., 50% formamide, 5 x SSPE, 5 x Denhardt's, 0.1% SDS, 100 ug/ml Salmon Sperm DNA, and a temperature of 42°C) or high stringency (see Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, NY, 1989); or (c) nucleic acid sequences are degenerate as a result of the genetic code to the nucleic acid sequences de ined in (a) or (b).
  • moderate e.g., 50% formamide, 5 x
  • DNA molecules are primarily referred to herein, as should be evident to one of skill in the art given the disclosure provided herein, a wide variety of related nucleic acid molecules may also be utilized in various embodiments described herein, including for example, RNA, nucleic acid analogues, as well as chimeric nucleic acid molecules which may be composed of more than one type of nucleic acid.
  • IL-1 Type 3 receptors and "soluble IL-1 Type 3 receptors” should be understood to include derivatives and analogs of the IL-1 Type 3 receptors described above.
  • Such derivatives include allelic variants and genetically engineered variants that contain conservative amino acid substitutions and/or minor additions, substitutions or deletions of amino acids, the net effect of which does not substantially change the biological activity (e.g., signal transduction) or function of the IL-1 Type 3 receptor.
  • Such derivatives are generally greater than about 50% homologous, preferably greater than 75% to 80% homologous, more preferably greater than 85% to 90% homologous, and most preferably greater than 92%, 95% or 97% homologous.
  • IL-1 Type 3 receptors may also be modified by derivatizing amino acid side chains, and/or the amino or carboxy termus with various functional groups, in order to allow for the formation of various conjugates (e.g., protein-IL-l-3R conjugates).
  • conjugates of IL-1-3R (and sIL-l-3R) may be constructed by recombinantly producing fusion proteins.
  • Such fusion proteins may comprise, for example, IL-l-3R-protein Z wherein protein Z is another cytokine receptor (e.g., IL-2R, IL-3R, IL-4R, IL-5R, 1L-6R, IL-7R, IL-8R, IL-9R, IL-10R, E_- 11R, IL-12R, IL-13R, IL-14R, IL-15R or TNF ( ⁇ or ⁇ ) receptor; see WO91/03553); a binding portion of an antibody; a toxin (as discussed below); or a protein or peptide which facilitates purification or identification of IL-1-3R (e.g., poly-His).
  • cytokine receptor e.g., IL-2R, IL-3R, IL-4R, IL-5R, 1L-6R, IL-7R, IL-8R, IL-9R, IL-10R, E_- 11R, IL-12R, IL-13R, IL-14
  • a fusion protein such as human IL-1 -3R (His) n or sIL-l-3R (His) n may be constructed in order to allow purification of the protein via the poly-His residue, for example, on a NTA nickel-chelating column.
  • the amino acid sequence of a IL-1 Type 3 receptor may also be linked to the peptide Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (DYKDDDDK) (Sequence I.D. No. 5) (Hopp et al., Bio/Technology 6: 1204, 1988) in order to facilitate purification of expressed recombinant protein.
  • the present invention also includes IL-1-3R (and sIL-l-3R) proteins which may be produced either with or without associated native-pattern glycosylation.
  • IL-1-3R and sIL-l-3R proteins which may be produced either with or without associated native-pattern glycosylation.
  • expression of EL-1-3R DNAs in bacteria such as E. coli provides non- glycosylated molecules.
  • IL-1-3R expressed in yeast or mammalian expression systems may vary in both glycosylation pattern and molecular weight from native EL-1-3R, depending on the amino acid sequence and expression system which is utilized.
  • N-glycosylation sites in eukaryotic proteins are generally characterized by the amino acid triplet Asn-A j -Z, where A ⁇ is any amino acid except Pro, and Z is Ser or Thr. In this triplet, asparagine provides a side chain amino group for covalent attachment of carbohydrate.
  • Such sites may be eliminated by deleting Asn or Z, substituting another amino acid for Asn or for residue Z, or inserting a non-Z amino acid between Aj and Z, or an amino acid other than Asn between Asn and A j .
  • Proteins which are substantially similar to IL-1-3R proteins may also be constructed by, for example, substituting or deleting various amino acid residues which are not required for biological activity. For example, cysteine residues may be deleted or replaced with other amino acids to prevent formation of incorrect intramolecular disulfide bridges upon renaturation. Similarly, adjacent dibasic amino acid residues may be modified for expression in yeast systems in which KEX2 protease activity is present.
  • nucleotide sequence which encodes IL-1-3R will be expressed in the final product.
  • nucleotide substitutions may be made in order to avoid secondary structure loops in the transcribed mRNA, or to provide codons that are more readily translated by the selected host, and thereby enhance expression within a selected host.
  • substitutions at the amino acid level should be made conservatively, i.e., the most preferred substitute amino acids are those which have characteristics resembling those of the residue to be replaced.
  • the potential effect of the deletion or insertion on biological activity should be considered utilizing, for example, the signalling assay disclosed within the Examples.
  • Mutations which are made to the sequence of the nucleic acid molecules of the present invention should generally preserve the reading frame phase of the coding sequences.
  • the mutations should preferably not create complementary regions that could hybridize to produce secondary mRNA structures, such as loops or hai ⁇ ins, which would adversely affect translation of the receptor mRNA.
  • a mutation site may be predetermined, it is not necessary that the nature of the mutation per se be predetermined.
  • random mutagenesis may be conducted at the target codon, and the expressed IL-1-3R mutants screened for the biological activity.
  • Representative methods for random mutagenesis include those described by Ladner et al. in U.S. Patent Nos. 5,096,815; 5,198,346; and 5,223,409.
  • mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion.
  • site-directed mutagenesis procedures may be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required.
  • Exemplary methods of making the alterations set forth above are disclosed by Walder et al. (Gene 42 ⁇ 33, 1986); Bauer et al. (Gene 37:73, 1985); Craik, Bio Techniques, January 1985, 12-19); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press, 1981); Sambrook et al. (Molecular cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, 1989); and U.S. Patent Nos. 4,518,584 and 4,737,462, which are inco ⁇ orated by reference herein.
  • IL-1 Type 3 receptors as well as substantially similar derivatives or analogs may be used as therapeutic reagents, immunogens, reagents in receptor-based immunoassays, or as binding agents for affinity purification procedures.
  • IL-1 Type 3 receptors of the present invention may be utilized to screen compounds for IL-1 Type 3 receptor agonist or antagonistic activity.
  • IL-1 Type 3 receptor proteins may also be covalently bound through reactive side groups to various insoluble substrates, such as cyanogen bromine-activated, bisoxirane-activated, carbonyldiimidazole-activated, or tosyl-activated, agarose structures, or by adsorbing to polyolefin surfaces (with or without glutaraldehyde cross-linking).
  • IL-1-3R may be used to selectively bind (for pu ⁇ oses of assay or purification) anti-IL-l-3R antibodies or IL- 1.
  • ISOLATION OF JX-1 TYPE 3 RECEPTOR CDNA CLONES As noted above, the present invention provides isolated nucleic acid molecules which encode IL-1 Type 3 receptors. Briefly, nucleic acid molecules which encode IL-1 Type 3 receptors of the present invention may be readily isolated from a variety of warm-blooded animals, including for example, humans, macaques, horses, cattle, sheep, pigs, dogs, cats, rats and mice. Particularly preferred tissues from which nucleic acid molecules which encode IL-1 Type 3 receptors may be isolated include brain, kidney and lung.
  • Nucleic acid molecules which encode IL-1 Type 3 receptors of the present invention may be readily isolated from conventionally prepared cDNA libraries (see, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, NY, 1989) or from commercially obtained libraries (e.g., Stratagene, LaJolla, Calif.) utilizing the disclosure provided herein. Particularly preferred methods for obtaining isolated DNA molecules which encode EL-1 Type 3 receptors of the present invention are described in more detail below in Example 1 (see also Sequence I.D. Nos. 1 and 3).
  • isolated nucleic acid molecules are provided which encode human EL-1 Type 3 receptors.
  • such nucleic acid molecules may be readily obtained by probing a human cDNA library either with a specific sequence as described below in Example 1, or with a rat sequence (e.g.. Sequence I.D. Nos. 2 or 4) under conditions of high stringency (e.g., 50% formamide, 5 x SSC, 5x Denharts, 0.1% SDS, 100 ug/ml salmon sperm DNA, at 42°C for 12 hours). This may be followed by extensive washing with 2x SSC containing 0.2% SDS at 50°C.
  • high stringency e.g. 50% formamide, 5 x SSC, 5x Denharts, 0.1% SDS, 100 ug/ml salmon sperm DNA, at 42°C for 12 hours. This may be followed by extensive washing with 2x SSC containing 0.2% SDS at 50°C.
  • Suitable cDNA libraries may be obtained from commercial sources (e.g., Stratagene, LaJolla, Calif; or Clontech, Palo Alto, Calif, or prepared utilizing standard techniques (see, e.g,. Sambrook et al., supra).
  • the present invention also provides recombinant expression vectors which include synthetic or cDNA-derived DNA fragments encoding IL-l Type 3 receptors or substantially similar proteins, which are operably linked to suitable transcriptional or translation regulatory elements derived from mammalian, microbial, viral or insect genes.
  • suitable transcriptional or translation regulatory elements include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites, and, within preferred embodiments, sequences which control the termination of transcription and translation.
  • the ability to replicate in a host usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants may additionally be inco ⁇ orated.
  • DNA regions are operably linked when they are functionally related to each other.
  • DNA for a signal peptide secretory leader
  • DNA for a polypeptide if it is expressed as a precursor which participates in the secretion of the polypeptide
  • a promoter is operably linked to a coding sequence if it controls the transcription of the sequence
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation.
  • operably linked means contiguous and, in the case of secretory leaders, contiguous and in reading frame.
  • Expression vectors may also contain DNA sequences necessary to direct the secretion of a polypeptide of interest.
  • DNA sequences may include at least one secretory signal sequence.
  • Representative secretory signals include the alpha factor signal sequence (pre-pro sequence; Kurjan and Herskowitz, Cell 30:933-943, 1982; Kurjan et al., U.S. Patent No. 4,546,082; Brake, EP 1 16,201), the PHO5 signal sequence (Beck et al., WO 86/00637), the BAR1 secretory signal sequence (MacKay et al., U.S. Patent No.
  • a secretory signal sequence may be synthesized according to the rules established, for example, by von Heinje (Eur. J. Biochem. 733: 17-21, 1983; J. Mol. Biol. 75 99-105, 1985; Nuc. Acids Res. 7 4683- 4690, 1986).
  • a nucleic acid molecule encoding a IL-l Type 3 receptor is inserted into a suitable expression vector, which in turn is used to transform or transfect appropriate host cells for expression.
  • Host cells for use in practicing the present invention include mammalian, avian, plant, insect, bacterial and fungal cells.
  • Preferred eukaryotic cells include cultured mammalian cell lines (e.g., rodent or human cell lines) and fungal cells, including species of yeast (e.g., Saccharomyces spp., particularly S. cerevisiae, Schizosaccharomyces spp., or Kluyveromyces spp.) or filamentous fungi (e.g., Aspergillus spp., Neurospora spp.).
  • yeast Saccharomyces cerevisiae are particularly preferred.
  • a host cell will be selected on the basis of its ability to produce the protein of interest at a high level or its ability to carry out at least some of the processing steps necessary for the biological activity of the protein. In this way, the number of cloned DNA sequences which must be transfected into the host cell may be minimized and overall yield of biologically active protein may be maximized.
  • Suitable yeast vectors for use in the present invention include YRp7 (Struhl et al., Proc. Natl. Acad. Sci. USA 76:1035-1039, 1978), YEpl3 (Broach et al., Gene 5: 121-133, 1979), POT vectors (Kawasaki et al., U.S. Patent No. 4,931,373, which is inco ⁇ orated by reference herein), pJDB249 and pJDB219 (Beggs, Nature 275: 104-108, 1978) and derivatives thereof.
  • Such vectors will generally include a selectable marker, which may be one of any number of genes that exhibit a dominant phenotype for which a phenotypic assay exists to enable transformants to be selected.
  • selectable markers are those that complement host cell auxotrophy, provide antibiotic resistance or enable a cell to utilize specific carbon sources, and include LEU2 (Broach et al., ibid.), URA3 (Botstein et al.. Gene 5: 17, 1979), HIS3 (Struhl et al., ibid.) or POT1 (Kawasaki et al., ibid).
  • Another suitable selectable marker is the CAT gene, which confers chloramphenicol resistance on yeast cells.
  • promoters for use in yeast include promoters from yeast glycolytic genes (Hitzeman et al., J. Biol. Chem. 255: 12073-12080, 1980; Alber and Kawasaki, J. Mol. Appl. Genet. 7:419-434, 1982; Kawasaki, U.S. Patent No. 4,599,311) or alcohol dehydrogenase genes (Young et al., in Genetic Engineering of Microorganisms for Chemicals, Hollaender et al. (eds.), p. 355, Plenum, New York, 1982; Ammerer, Meth. Enzymol. 707: 192-201, 1983).
  • promoters are the TPI1 promoter (Kawasaki, U.S. Patent No. 4,599,311, 1986) and the ADH2-4 C promoter (Russell et al., Nature 30*652-654, 1983; Irani and Kilgore, U.S. Patent Application Serial No. 07/784,653, which is inco ⁇ orated herein by reference).
  • the expression units may also include a transcriptional terminator, such as the 77Y7 terminator (Alber and Kawasaki, ibid.).
  • proteins of the present invention can be expressed in filamentous fungi, for example, strains of the fungi Aspergillus (McKnight et al., U.S. Patent No.
  • useful promoters include those derived from Aspergillus nidulans glycolytic genes, such as the ADH3 promoter (McKnight et al., EMBOJ. *2093-2099, 1985) and the tpiA promoter.
  • An example of a suitable terminator is the ADH3 terminator (McKnight et al., ibid., 1985).
  • the expression units utilizing such components are cloned into vectors that are capable of insertion into the chromosomal DNA of Aspergillus.
  • the genotype of the host cell will generally contain a genetic defect that is complemented by the selectable marker present on the expression vector Choice of a particular host and selectable marker is well within the level of ordinary skill in the art
  • the host strain carries a mutation, such as the yeast pep4 mutation (Jones, Genetics 85 23-33, 1977), which results in reduced proteolytic activity
  • cultured mammalian cells may be used as host cells within the present invention
  • Preferred cultured mammalian cells for use in the present invention include the COS-1 (ATCC No CRL 1650), COS-7 (ATCC No CRL 1651), BHK (ATCC No CRL 1632), and 293 (ATCC No CRL 1573, Graham et al , J. Gen. Virol.
  • a preferred BHK cell line is the BHK 570 cell line (deposited with the American Type Culture Collection under accession number CRL 10314)
  • a number of other mammalian cell lines may be used within the present invention, including Rat Hep I (ATCC No CRL 1600), Rat Hep II (ATCC No CRL 1548), TCMK (ATCC No CCL 139), Human lung (ATCC No CCL 75 1), Human hepatoma (ATCC No HTB-52), Hep G2 (ATCC No HB 8065), Mouse liver (ATCC No CCL 29 1), NCTC 1469 (ATCC No CCL 9 1), SP2/0-Agl4 (ATCC No 1581), HIT-T15 (ATCC No CRL 1777), Ltk- (ATCC) No CCL 1 3) and RINm 5AHT 2 B (Orskov and Nielson, FEBS 229(1) 175-178, 1988)
  • Mammalian expression vectors for use in carrying out the present invention should include a promoter capable of directing the transcription of a cloned gene or cDNA
  • Preferred promoters include viral promoters and cellular promoters
  • Viral promoters include the immediate early cytomegalovirus promoter (Boshart et al , Cell 41 521-530, 1985) and the SV40 promoter (Subramani et al , Mol Cell. Biol. 1 854-864, 1981)
  • Cellular promoters include the mouse metallothionein-1 promoter (Palmiter et al., U S Patent No 4,579,821), a mouse V j promoter (Bergman et al , Proc. Natl. Acad.
  • a particularly preferred promoter is the major late promoter from Adenovirus 2 (Kaufman and Sha ⁇ , Mol. Cell. Biol.
  • Such expression vectors may also contain a set of RNA splice sites located downstream from the promoter and upstream from the DNA sequence encoding the peptide or protein of interest Preferred RNA splice sites may be obtained from SV40, adenovirus and/or immunoglobulin genes Alternatively, within certain embodiments RNA splice sites may be located downstream from the DNA sequence encoding the peptide or protein of interest. Also contained in the expression vectors is a polyadenylation signal located downstream of the coding sequence of interest.
  • Suitable polyadenylation signals include the early or late polyadenylation signals from SV40 (Kaufman and Sha ⁇ , ibid.), the polyadenylation signal from the Adenovirus 5 E1B region and the human growth hormone gene terminator (DeNoto et al., Nuc. Acids Res. 9:3719-3730, 1981).
  • the expression vectors may include a noncoding viral leader sequence, such as the Adenovirus 2 tripartite leader, located between the promoter and the RNA splice sites.
  • Preferred vectors may also include enhancer sequences, such as the SV40 enhancer and the mouse 1 enhancer (Gillies, Cell 33:717-728, 1983).
  • Expression vectors may also include sequences encoding the adenovirus VA RNAs. Suitable vectors can be obtained from commercial sources (e.g., Invitrogen, San Diego, CA; Stratagene, La Jolla, CA).
  • Cloned DNA sequences may be introduced into cultured mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7:603, 1981; Graham and Van der Eb, Virology 52:456, 1973), electroporation (Neumann et al., EMBO J. 7:841-845, 1982), or DEAE-dextran mediated transfection (Ausubel et al. (eds ), Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987), which are inco ⁇ orated herein by reference.
  • a selectable marker is generally introduced into the cells along with the gene or cDNA of interest.
  • Preferred selectable markers for use in cultured mammalian cells include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate.
  • the selectable marker may be an amplifiable selectable marker.
  • Preferred amplifiable selectable markers are the DHFR gene and the neomycin resistance gene. Selectable markers are reviewed by Thilly (Mammalian Cell Technology, Butterworth Publishers, Stoneham, MA, which is inco ⁇ orated herein by reference). The choice of selectable markers is well within the level of ordinary skill in the art.
  • Selectable markers may be introduced into the cell on a separate vector at the same time as the IL-l Type 3 receptor sequence, or they may be introduced on the same vector. If on the same vector, the selectable marker and the IL-l Type 3 receptor sequence may be under the control of different promoters or the same promoter, the latter arrangement producing a dicistronic message. Constructs of this type are known in the art (for example, Levinson and Simonsen, U.S. Patent No. 4,713,339). It may also be advantageous to add additional DNA, known as "carrier DNA" to the mixture which is introduced into the cells. Transfected mammalian cells are allowed to grow for a period of time, typically 1-2 days, to begin expressing the DNA sequence(s) of interest.
  • Drug selection is then applied to select for growth of cells that are expressing the selectable marker in a stable fashion.
  • the drug concentration may be increased in a stepwise manner to select for increased copy number of the cloned sequences, thereby increasing expression levels.
  • Cells expressing the introduced sequences are selected and screened for production of the protein of interest in the desired form or at the desired level. Cells which satisfy these criteria may then be cloned and scaled up for production.
  • Preferred prokaryotic host cells for use in carrying out the present invention are strains of the bacteria Escherichia coli, although Bacillus and other genera are also useful.
  • Vectors used for expressing cloned DNA sequences in bacterial hosts will generally contain a selectable marker, such as a gene for antibiotic resistance, and a promoter that functions in the host cell.
  • a selectable marker such as a gene for antibiotic resistance
  • Appropriate promoters include the t ⁇ (Nichols and Yanofsky, Meth. Enzymol. 707: 155-164, 1983), lac (Casadaban et al., J. Bacteriol.
  • Plasmids useful for transforming bacteria include pBR322 (Bolivar et al., Gene 2:95-113, 1977), the pUC plasmids (Messing, Meth. Enzymol. 707:20-78, 1983; Vieira and Messing, Gene 79:259-268, 1982), pCQV2 (Queen, ibid , pMAL-2 (New England Biolabs, Beverly, MA) and derivatives thereof. Plasmids may contain both viral and bacterial elements.
  • promoters, terminators and methods for introducing expression vectors encoding IL-l Type 3 receptors of the present invention into plant, avian and insect cells would be evident to those of skill in the art.
  • the use of baculoviruses, for example, as vectors for expressing heterologous DNA sequences in insect cells has been reviewed by Atkinson et al. (Pestic. Sci. 25:215- 224,1990).
  • the use of Agrohacterium rhizogenes as vectors for expressing genes in plant cells has been reviewed by Sinkar et al. (J. Biosci. (Bangalore) 11 :47-58, 1987).
  • Host cells containing DNA molecules of the present invention are then cultured to express a DNA molecule encoding a IL-l Type 3 receptor.
  • the cells are cultured according to standard methods in a culture medium containing nutrients required for growth of the chosen host cells.
  • suitable media are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals, as well as other components, e.g., growth factors or serum, that may be required by the particular host cells.
  • the growth medium will generally select for cells containing the DNA molecules by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker on the DNA construct or co-transfected with the DNA construct.
  • Suitable growth conditions for yeast cells include culturing in a chemically defined medium, comprising a nitrogen source, which may be a non- amino acid nitrogen source or a yeast extract, inorganic salts, vitamins and essential amino acid supplements at a temperature between 4°C and 37°C, with 30°C being particularly preferred.
  • the pH of the medium is preferably maintained at a pH greater than 2 and less than 8, more preferably pH 5-6.
  • Methods for maintaining a stable pH include buffering and constant pH control.
  • Preferred agents for pH control include sodium hydroxide.
  • Preferred buffering agents include succinic acid and Bis-Tris (Sigma Chemical Co., St. Louis, MO).
  • yeast host cells Due to the tendency of yeast host cells to hyperglycosylate heterologous proteins, it may be preferable to express the IL-l Type 3 receptors of the present invention in yeast cells having a defect in a gene required for asparagine-linked glycosylation.
  • Such cells are preferably grown in a medium containing an osmotic stabilizer.
  • a preferred osmotic stabilizer is sorbitol supplemented into the medium at a concentration between 0.1 M and 1.5 M, preferably at 0.5 M or 1.0 M.
  • Cultured mammalian cells are generally cultured in commercially available serum- containing or serum-free media. Selection of a medium and growth conditions appropriate for the particular cell line used is within the level of ordinary skill in the art.
  • D -1 Type 3 receptors may also be expressed in non-human transgenic animals, particularly transgenic warm-blooded animals.
  • Methods for producing transgenic animals including mice, rats, rabbits, sheep and pigs, are known in the art and are disclosed, for example, by Hammer et al. (Nature 375:680-683, 1985), Palmiter et al. (Science 222:809-814, 1983), Brinster et al. (Proc. Natl. Acad Sci. USA 52:4438- 4442, 1985), Palmiter and Brinster (Cell */:343-345, 1985) and U.S. Patent No. 4,736,866, which are inco ⁇ orated herein by reference.
  • an expression unit including a DNA sequence to be expressed together with appropriately positioned expression control sequences, is introduced into pronuclei of fertilized eggs.
  • Introduction of DNA is commonly done by microinjection. Integration of the injected DNA is detected by blot analysis of DNA from tissue samples, typically samples of tail tissue. It is generally preferred that the introduced DNA be inco ⁇ orated into the germ line of the animal so that it is passed on to the animal's progeny.
  • knockout animals may be developed from embryonic stem cells through the use of homologous recombination (Capecchi, Science 244: 1288-1292, 1989) or antisense oligonucleotide (Stein and Chen, Science 267(5124): 1004- 1012, 1993; Milligan et al., Semin. Cone. Biol. 3(6):391-398, 1992).
  • a transgenic animal such as a mouse
  • a transgenic animal is developed by targeting a mutation to disrupt a IL-l Type 3 receptor sequence (see Mansour et al., "Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: A general strategy for targeting mutations to non-selectable genes," Nature 336:348-352, 1988).
  • Such animals may readily be utilized as a model to study the role of the IL-l Type 3 receptor in metabolism.
  • IL-l Type 3 receptor peptides should be understood to include portions of a IL-l Type 3 receptor or derivatives thereof discussed above, which do not contain transmembrane domains, and which are at least 8, and more preferably 10 or greater amino acids in length.
  • IL-l Type 3 receptor as well as putative transmembrane domains may be predicted from the primary translation products using the hydrophopicity plot function of, for example, PROTEAN (DNA STAR, Madison, WI), or according to the methods described by Kyte and Doolittle (J. Mol. Biol. 757:105- 132, 1982). While not wishing to be bound by a graphical representation, based upon this hydrophopicity analysis, IL-l Type 3 receptors are believed to have the general structure shown in Figure 1. In particular, these receptors are believed to comprise an extracellular amino-terminal domain, a transmembrane domain, and an intracellular domain.
  • isolated IL-l Type 3 receptor peptides comprising the extracellular amino-terminal domain of a IL-l Type 3 receptor.
  • an isolated IL-l Type 3 receptor peptide is provided comprising the sequence of amino acids shown in Sequence I.D. No.2, from amino acid number 1 to amino acid number 336.
  • isolated IL-l Type 3 receptor peptides are provided comprising the sequence of amino acids shown in Sequence I.D. No. 4, from amino acid number 1 to amino acid number 338.
  • IL-l Type 3 receptor peptides may be prepared by, among other methods, culturing suitable host vector systems to produce the recombinant translation products of the present invention. Supernatants from such cell lines may then be treated by a variety of purification procedures in order to isolate the IL-l Type 3 receptor peptide. For example, the supernatant may be first concentrated using commercially available protein concentration filters, such as an Amicon or Millipore Pellicon ultrafiltration unit. Following concentration, the concentrate may be applied to a suitable purification matrix such as, for example, IL-l or an anti-IL-1 Type 3 receptor antibody bound to a suitable support. Alternatively, anion or cation exchange resins may be employed in order to purify the receptor or peptide. Finally, one or more reversed-phase high performance liquid chromatography (RP-HPLC) steps may be employed to further purify the IL-l Type 3 receptor peptide.
  • RP-HPLC reversed-phase high performance liquid chromatography
  • IL-l Type 3 receptor peptides may also be prepared utilizing standard polypeptide synthesis protocols, and purified utilizing the above- described procedures.
  • a IL-l Type 3 receptor peptide is deemed to be "isolated” or purified within the context of the present invention, if only a single band is detected subsequent to SDS-polyacrylamide gel analysis followed by staining with Coomassie Brilliant Blue.
  • IL-l Type 3 receptors including derivatives thereof, as well as portions or fragments of these proteins such as the IL-l Type 3 receptor peptides discussed above, may be utilized to prepare antibodies which specifically bind to IL-l Type 3 receptors.
  • antibodies includes polyclonal antibodies, monoclonal antibodies, fragments thereof such as F(ab') 2 and Fab fragments, as well as recombinantly produced binding partners. These binding partners inco ⁇ orate the variable regions from a gene which encodes a specifically binding monoclonal antibody.
  • Antibodies are defined to be specifically binding if they bind to the IL-l Type 3 receptor with a K A of greater than or equal to IO 7 M" 1 and preferably greater than or equal to 10 8 M _1 , and bind to IL-l Type I or Type II receptors with an affinity of less than K A IO 7 M" 1 , and preferably less than 10 5 M _1 or 10 3 M” 1 .
  • the affinity of a monoclonal antibody or binding partner may be readily determined by one of ordinary skill in the art (see Scatchard, Ann. NY. Acad. Sci. 57:660-672, 1949).
  • Polyclonal antibodies may be readily generated by one of ordinary skill in the art from a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, or rats.
  • the IL-l Type 3 receptor is utilized to immunize the animal through intraperitoneal, intramuscular, intraocular, or subcutaneous injections.
  • the immunogenicity of a IL-l Type 3 receptor or IL-l Type 3 receptor peptide may be increased through the use of an adjuvant such as Freund's complete or incomplete adjuvant.
  • small samples of serum are collected and tested for reactivity to the IL-l Type 3 receptor.
  • assays may be utilized in order to detect antibodies which specifically bind to a IL-l Type 3 receptor. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane (eds ), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: Countercurrent Immuno-Electrophoresis (CIEP), Radioimmunoassays, Radioimmunoprecipitations, Enzyme-Linked Immuno-Sorbent Assays (ELISA), Dot Blot assays, Inhibition or Competition assays, and sandwich assays (see U.S. Patent Nos. 4,376, 1 10 and 4,486,530; see also Antibodies: A Laboratory Manual, supra).
  • CIEP Countercurrent Immuno-Electrophoresis
  • ELISA Enzyme-Linked Immuno-Sorbent Assays
  • Dot Blot assays Inhibition or Competition assays
  • sandwich assays see U.S. Patent Nos. 4,376, 1 10 and 4,486,530
  • Particularly preferred polyclonal antisera will give a signal that is at least three times greater than background. Once the titer of the animal has reached a plateau in terms of its reactivity to the IL-l Type 3 receptor, larger quantities of polyclonal antisera may be readily obtained either by weekly bleedings, or by exsanguinating the animal.
  • Monoclonal antibodies may also be readily generated using well-known techniques (see U.S. Patent Nos. RE 32,01 1, 4,902,614, 4,543,439, and 4,41 1,993; see also Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Plenum Press, Kennett, McKearn, and Bechtol (eds ), 1980, and Antibodies: A Laboratory Manual, Harlow and Lane (eds ), Cold Spring Harbor Laboratory Press, 1988). Briefly, within one embodiment a subject animal such as a rat or mouse is injected with a form of IL-l Type 3 receptor suitable for generating an immune response against the IL-l Type 3 receptor.
  • suitable forms include, among others, cells which express the IL-l Type 3 receptor, or peptides which are based upon the IL-l Type 3 receptor sequence. Additionally, many techniques are known in the art for increasing the resultant immune response, for example, by coupling the receptor or receptor peptides to another protein such as ovalbumin or keyhole limpet hemocyanin (KLH), or through the use of adjuvants such as Freund's complete or incomplete adjuvant. The initial immunization may be through intraperitoneal, intramuscular, intraocular, or subcutaneous routes.
  • KLH keyhole limpet hemocyanin
  • the animal may be reimmunized with another booster immunization.
  • the animal may then be test bled and the serum tested for binding to the IL-l Type 3 receptor using assays as described above. Additional immunizations may also be accomplished until the animal has plateaued in its reactivity to the IL-l Type 3 receptor.
  • the animal may then be given a final boost of IL-l Type 3 receptor or IL-l Type 3 receptor peptide, and three to four days later sacrificed.
  • the spleen and lymph nodes may be harvested and disrupted into a single cell suspension by passing the organs through a mesh screen or by rupturing the spleen or lymph node membranes which encapsidate the cells.
  • the red cells are subsequently lysed by the addition of a hypotonic solution, followed by immediate return to isotonicity.
  • suitable cells for preparing monoclonal antibodies are obtained through the use of in vitro immunization techniques. Briefly, an animal is sacrificed, and the spleen and lymph node cells are removed as described above. A single cell suspension is prepared, and the cells are placed into a culture containing a form of the IL-l Type 3 receptor that is suitable for generating an immune response as described above. Subsequently, the lymphocytes are harvested and fused as described below. Cells which are obtained through the use of in vitro immunization or from an immunized animal as described above may be immortalized by transfection with a virus such as the Epstein-Barr virus (EBV) (see Glasky and Reading, Hybridoma 5(4):377-389, 1989).
  • EBV Epstein-Barr virus
  • the harvested spleen and/or lymph node cell suspensions are fused with a suitable myeloma cell in order to create a "hybridoma" which secretes monoclonal antibodies.
  • Suitable myeloma lines are preferably defective in the construction or expression of antibodies, and are additionally syngeneic with the cells from the immunized animal. Many such myeloma cell lines are well known in the art and may be obtained from sources such as the American Type Culture Collection (ATCC), Rockville, Maryland (see Catalogue of Cell Lines & Hybridomas, 6th ed., ATCC, 1 88).
  • Representative myeloma lines include: for humans, UC 729-6 (ATCC No.
  • CRL 8061 MC/CAR-Z2 (ATCC No. CRL 8147), and SKO-007 (ATCC No. CRL 8033); for mice, SP2/0-Agl4 (ATCC No. CRL 1581), and P3X63Ag8 (ATCC No. TIB 9); and for rats, Y3-Agl .2.3 (ATCC No. CRL 1631), and YB2/0 (ATCC No. CRL 1662).
  • Particularly preferred fusion lines include NS-1 (ATCC No. TIB 18) and P3X63 - Ag 8.653 (ATCC No. CRL 1580), which may be utilized for fusions with either mouse, rat, or human cell lines.
  • Fusion between the myeloma cell line and the cells from the immunized animal may be accomplished by a variety of methods, including the use of polyethylene glycol (PEG) (see Antibodies: A Laboratory Manual, Harlow and Lane (eds ), Cold Spring Harbor Laboratory Press, 1988) or electrofusion (see Zimmerman and Vienken, J. Membrane Biol. 67: 165-182, 1982).
  • PEG polyethylene glycol
  • the cells are placed into culture plates containing a suitable medium, such as RPMI 1640 or DMEM (Dulbecco's Modified Eagles Medium) (JRH Biosciences, Lenexa, KS).
  • a suitable medium such as RPMI 1640 or DMEM (Dulbecco's Modified Eagles Medium) (JRH Biosciences, Lenexa, KS).
  • the medium may also contain additional ingredients, such as Fetal Bovine Serum ("FBS,” i.e., from Hyclone, Logan, Utah, or JRH Biosciences), thymocytes which were harvested from a baby animal of the same species as was used for immunization, or agar to solidify the medium.
  • FBS Fetal Bovine Serum
  • thymocytes which were harvested from a baby animal of the same species as was used for immunization
  • agar to solidify the medium agar to solidify the medium.
  • the medium should contain a reagent which
  • HAT hypoxanthine, aminopterin, and thymidine
  • HAT hypoxanthine, aminopterin, and thymidine
  • the resulting fused cells or hybridomas may be screened in order to determine the presence of antibodies which recognize the IL-l Type 3 receptor.
  • a hybridoma producing antibodies which bind to IL-l Type 3 receptor may be isolated.
  • mRNA is isolated from a B cell population and utilized to create heavy and light chain immunoglobulin cDNA expression libraries in the kIMMUNOZAP(H) and kIMMUNOZAP(L) vectors.
  • vectors may be screened individually or co- expressed to form Fab fragments or antibodies (see Huse et al., supra, see also Sastry et al., supra). Positive plaques may subsequently be converted to a non-lytic plasmid which allows high level expression of monoclonal antibody fragments from E. coli.
  • binding partners may also be constructed utilizing recombinant DNA techniques to inco ⁇ orate the variable regions of a gene which encodes a specifically binding antibody.
  • the construction of these proteins may be readily accomplished by one of ordinary skill in the art (see Larrick et al., "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells," Biotechnology 7:934-938, September 1989; Riechmann et al., “Reshaping Human Antibodies for Therapy," Nature 332:323- 327, 1988; Roberts et al., “Generation of an Antibody with Enhanced Affinity and Specificity for its Antigen by Protein Engineering," Nature 325:731-734, 1987; Verhoeyen et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity," Science 239:1534-1536, 1988; Chaudhary et al., "A Recombin
  • Patent No. 5,132,405 entitled “Biosynthetic Antibody Binding Sites” DNA molecules encoding IL-l Type 3 receptor-specific antigen binding domains are amplified from hybridomas which produce a specifically binding monoclonal antibody, and inserted directly into the genome of a cell which produces human antibodies (see Verhoeyen et al., supra, see also Reichmann et al., supra). This technique allows the antigen-binding site of a specifically binding mouse or rat monoclonal antibody to be transferred into a human antibody. Such antibodies are preferable for therapeutic use in humans because they are not as antigenic as rat or mouse antibodies.
  • the antigen-binding sites may be either linked to, or inserted into, another completely different protein (see Chaudhary et al., supra), resulting in a new protein with antigen-binding sites of the antibody as well as the functional activity of the completely different protein.
  • the antigen-binding sites or IL-l Type 3 receptor binding domain of the antibody may be found in the variable region of the antibody.
  • DNA sequences which encode smaller portions of the antibody or variable regions which specifically bind to mammalian IL-l Type 3 receptor may also be utilized within the context of the present invention. These portions may be readily tested for binding specificity to the IL-l Type 3 receptor utilizing assays described below.
  • genes which encode the variable region from a hybridoma producing a monoclonal antibody of interest are amplified using oligonucleotide primers for the variable region.
  • oligonucleotide primers for the variable region may be synthesized by one of ordinary skill in the art, or may be purchased from commercially available sources.
  • Stratacyte (La Jolla, CA) sells primers for mouse and human variable regions including, among others, primers for V Ha , V Hb , V Hc , V Hd , C Hl , V L and C L regions.
  • primers may be utilized to amplify heavy or light chain variable regions, which may then be inserted into vectors such as IMMUNOZAP*(H) or IMMUNOZAP*(L) (Stratacyte), respectively. These vectors may then be introduced into E. coli for expression. Utilizing these techniques, large amounts of a single-chain protein containing a fusion of the V H and V L domains may be produced (see Bird et al., Science 242:423-426, 1988).
  • Other "antibodies” which may also be prepared utilizing the disclosure provided herein, and thus which are also deemed to fall within the scope of the present invention include humanized antibodies (e.g., U.S. Patent No.
  • WO 94/10332 4,816,567 and WO 94/10332
  • micobodies e.g., WO 94/0981
  • transgenic antibodies e.g., GB 2 272 440.
  • suitable antibodies may be isolated or purified by many techniques well known to those of ordinary skill in the art (see Antibodies: A Laboratory Manual, supra). Suitable techniques include peptide or protein affinity columns, HPLC or RP-HPLC, purification on protein A or protein G columns, or any combination of these techniques.
  • the term "isolated" as used to define antibodies or binding partners means "substantially free of other blood components.” Antibodies of the present invention have many uses.
  • antibodies may be utilized in flow cytometry to sort IL-l Type 3 receptor-bearing cells, or to histochemically stain IL-l Type 3 receptor-bearing tissues. Briefly, in order to detect IL-l Type 3 receptors on cells, the cells (or tissue) are incubated with a labeled antibody which specifically binds to IL-l Type 3 receptors, followed by detection of the presence of bound antibody. These steps may also be accomplished with additional steps such as washings to remove unbound antibody. Representative examples of suitable labels, as well as methods for conjugating or coupling antibodies to such labels are described in more detail below.
  • purified antibodies may also be utilized therapeutically to block the binding of IL-l or other IL-l Type 3 receptor substrates to the IL-l Type 3 receptor in vitro or in vivo.
  • assays may be utilized to detect antibodies which block or inhibit the binding of IL-l to the IL-l Type 3 receptor, including inter alia, inhibition and competition assays noted above.
  • monoclonal antibodies (prepared as described above) are assayed for binding to the IL-l Type 3 receptor in the absence of IL-l, as well as in the presence of varying concentrations of IL-l.
  • Blocking antibodies are identified as those which, for example, bind to IL-l Type 3 receptors and, in the presence of IL-l, block or inhibit the binding of IL-l to the IL-l Type 3 receptor.
  • Antibodies of the present invention may also be coupled or conjugated to a variety of other compounds (or labels) for either diagnostic or therapeutic use.
  • Such compounds include, for example, toxic molecules, molecules which are nontoxic but which become toxic upon exposure to a second compound, and radionuclides. Representative examples of such molecules are described in more detail below.
  • Antibodies which are to be utilized therapeutically are preferably provided in a therapeutic composition comprising the antibody or binding partner and a physiologically acceptable carrier or diluent.
  • suitable carriers or diluents include, among others, neutral buffered saline or saline, and may also include additional excipients or stabilizers such as buffers, sugars such as glucose, sucrose, or dextrose, chelating agents such as EDTA, and various preservatives.
  • nucleic acid molecules, antibodies, and IL-l Type 3 receptors (including sIL-1 3R) of the present invention may be labeled or conjugated (either through covalent or non-covalent means) to a variety of labels or other molecules, including for example, fluorescent markers, enzyme markers, toxic molecules, molecules which are nontoxic but which become toxic upon exposure to a second compound, and radionuclides.
  • fluorescent labels suitable for use within the present invention include, for example, Fluorescein Isothiocyanate (FITC), Rhodamine, Texas Red, Luciferase and Phycoerythrin (PE). Particularly preferred for use in flow cytometry is FITC which may be conjugated to purified antibody according to the method of Keltkamp in "Conjugation of Fluorescein Isothiocyanate to Antibodies. I. Experiments on the Conditions of Conjugation," Immunology 75:865-873, 1970. (See also Keltkamp, "Conjugation of Fluorescein Isothiocyanate to Antibodies. II.
  • FITC Fluorescein Isothiocyanate
  • Rhodamine Rhodamine
  • Texas Red Luciferase
  • PE Phycoerythrin
  • HRP Peroxidase-Labeled Antibody: A New Method of Conjugation
  • Representative examples of enzyme markers or labels include alkaline phosphatase, horse radish peroxidase, and ⁇ -galactosidase.
  • Representative examples of toxic molecules include ricin, abrin, diphtheria toxin, cholera toxin, gelonin, pokeweed antiviral protein, tritin, Shigella toxin, and Pseudomonas exotoxin A.
  • Representative examples of molecules which are nontoxic, but which become toxic upon exposure to a second compound include thymidine kinases such as HSVTK and VZVTK.
  • radionuclides include Cu-64, Ga-67, Ga-68, Zr-89, Ru-97, Tc-99m, Rh-105, Pd-109, In-I l l, 1-123, 1-125, 1-131, Re-186, Re-188, Au-198, Au- 199, Pb-203, At-211, Pb-212 and Bi-212.
  • nucleic acid molecules, antibodies, and IL-l Type 3 receptors may also be labeled with other molecules such as colloidal gold, as well either member of a high affinity binding pair (e.g., avidin-biotin).
  • DIAGNOSTIC USE OF IL-l TYPE 3 RECEPTOR SEQUENCES within another aspect of the present invention, probes and primers are provided for detecting IL-l Type 3 receptors.
  • probes are provided which are capable of hybridizing to IL-l Type 3 receptor DNA or RNA.
  • probes are "capable of hybridizing" to IL- 1 Type 3 receptor DNA if they hybridize to Sequence I.D. Nos. 1 or 3 under conditions of moderate or high stringency (see Sambrook et al., supra); but not to IL-l Type I or Type ⁇ receptor nucleic acid sequences.
  • the probe may be utilized to hybridize to suitable nucleotide sequences in the presence of 50% formamide, 5x SSPE, 5x Denhardt's, 0.1% SDS and 100 ug/ml Salmon Sperm DNA at 42°C, followed by a first wash with 2x SSC at 42°C, and a second wash with 0.2x SSC at 55 to 60°C.
  • Probes of the present invention may be composed of either deoxyribonucleic acids (DNA) ribonucleic acids (RNA), nucleic acid analogues, or any combination of these, and may be as few as about 12 nucleotides in length, usually about 14 to 18 nucleotides in length, and possibly as large as the entire sequence of the IL-l Type 3 receptor. Selection of probe size is somewhat dependent upon the use of the probe. For example, in order to determine the presence of various polymo ⁇ hic forms of the IL-l Type 3 receptor within an individual, a probe comprising virtually the entire length of the IL-l Type 3 receptor coding sequence is preferred.
  • IL-l Type 3 receptor probes may be utilized to identify polymo ⁇ hisms linked to the IL-l Type 3 receptor gene (see, for example, Weber, Genomics 7:524-530, 1990; and Weber and May, Amer. J. Hum. Gen. 4*388-396, 1989). Such polymo ⁇ hisms may be associated with inherited diseases such as diabetes.
  • Probes may be constructed and labeled using techniques which are well known in the art. Shorter probes of, for example, 12 or 14 bases may be generated synthetically. Longer probes of about 75 bases to less than 1.5 kb are preferably generated by, for example, PCR amplification in the presence of labeled precursors such as 32 P-dCTP, digoxigenin-dUTP, or biotin-dATP. Probes of more than 1.5 kb are generally most easily amplified by transfecting a cell with a plasmid containing the relevant probe, growing the transfected cell into large quantities, and purifying the relevant sequence from the transfected cells (see Sambrook et al., supra).
  • Probes may be labeled by a variety of markers, including, for example, radioactive markers, fluorescent markers, enzymatic markers, and chromogenic markers. The use of 32 P is particularly preferred for marking or labeling a particular probe. Probes of the present invention may also be utilized to detect the presence of a IL-l Type 3 receptor mRNA or DNA within a sample. However, if IL-l Type 3 receptors are present in only a limited number, or if it is desired to detect a selected mutant sequence which is present in only a limited number, or if it is desired to clone a IL-l Type 3 receptor from a selected warm-blooded animal, then it may be beneficial to amplify the relevant sequence such that it may be more readily detected or obtained.
  • markers including, for example, radioactive markers, fluorescent markers, enzymatic markers, and chromogenic markers. The use of 32 P is particularly preferred for marking or labeling a particular probe. Probes of the present invention may also be utilized to detect the presence of a
  • RNA amplification see Lizardi et al., Bio/Technology 6:1197-1202, 1988; Kramer et al., Nature 339:401-402, 1989; Lomeli et al., Clinical Chem. 35(9): 1826-1831, 1989; U.S. Patent No. 4,786,600
  • PCR Polymerase Chain Reaction
  • PCR amplification is utilized to detect or obtain a IL-l Type 3 receptor DNA.
  • a DNA sample is denatured at 95°C in order to generate single stranded DNA.
  • Specific primers as discussed below, are then annealed at 37°C to 70°C, depending on the proportion of AT/GC in the primers.
  • the primers are extended at 72°C with Taq polymerase in order to generate the opposite strand to the template. These steps constitute one cycle, which may be repeated in order to amplify the selected sequence.
  • Primers for the amplification of a selected sequence should be selected from sequences which are highly specific and form stable duplexes with the target sequence.
  • primers should also be non-complementary, especially at the 3' end, should not form dimers with themselves or other primers, and should not form secondary structures or duplexes with other regions of DNA.
  • primers of about 18 to 20 nucleotides are preferred, and may be easily synthesized using techniques well known in the art.
  • the present invention provides pharmaceutical compositions, as well as methods for using the same (for either prophylactic or therapeutic use).
  • the pharmaceutical compositions of the present invention may comprise an IL-l 3R, sIL-1 3R, antibody which is capable of specifically binding IL- 1 3R, IL-l 3R antagonists or agonists, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
  • Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like, carbohydrates such as glucose, mannose, sucrose or dextrose, proteins, polypeptides or amino acids, antioxidants, chelating agents such as EDTA or glutathione, and preservatives.
  • compositions of the present invention may be formulated for the manner of administration indicated, including for example, for oral, nasal, venous, vaginal or rectal administration.
  • the compositions may be administered as part of a sustained release implant (e.g., intra-articularly).
  • the compositions may be formulized as a lyophilizate, utilizing appropriate excipients which provide stability as a lyophilizate, and subsequent to rehydration.
  • compositions of the present invention may be utilized in order to treat a wide variety of diseases including, for example, immune-associated diseases such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, myasthemia gravis, scleritis, scleroderma, septic shock, allograft rejection, and graft versus host (GVH) disease.
  • diseases including, for example, immune-associated diseases such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, myasthemia gravis, scleritis, scleroderma, septic shock, allograft rejection, and graft versus host (GVH) disease.
  • rheumatoid arthritis such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, myasthemia gravis, scleritis, scleroderma, septic shock, allograft rejection, and graft versus host (GVH) disease
  • viral vectors are provided which may be utilized to treat diseases wherein either the IL-l Type 3 receptor (or a mutant IL-l Type 3 receptor) is over-expressed, or where no IL-l Type 3 receptor is expressed.
  • viral vectors are provided which direct the production of antisense IL-l Type 3 receptor RNA, in order to prohibit the over-expression of IL-l Type 3 receptors, or the expression of mutant IL-l Type 3 receptors.
  • viral vectors are provided which direct the expression of IL-l Type 3 receptor cDNA.
  • Viral vectors suitable for use in the present invention include, among others, recombinant vaccinia vectors (U.S. Patent Nos.
  • compositions may be administered in vivo, or ex vivo.
  • routes for in vivo administration include intradermally ("i.d.”), intracranially ("i.e.”), intraperitoneally (“i.p.”), intrathecally ("i.t.”), intravenously (“i.v “), subcutaneously (“s.c”) or intramuscularly (“i.m “).
  • the vectors which contain or express nucleic acid molecules of the present invention, or even the nucleic acid molecules themselves may be administered by a variety of alternative techniques, including for example direct DNA injection (Acsadi et al., Nature 352:815-818, 1991); microprojectile bombardment (Williams et al., PNAS 55:2726-2730, 1991); liposomes (Pickering et al., Circ. 59(1):13-21, 1994; and Wang et al., PNAS 5*7851-7855, 1987); lipofection (Feigner et al., Proc. Natl. Acad. Sci.
  • RNA is then isolated from the lung utilizing a Promega RNAgents Total RNA Kit (catalog #Z51 10, Promega, Wise.) according to the manufacturers instructions, followed by the isolation of poly A+ RNA utilizing a Promega PolyATract kit (catalog # Z5420).
  • a cDNA phage library is then prepared utilizing a Giga-Pack Gold library construction kit according to the manufacturers' instructions (catalog #23761 1, Stratagene, LaJolla, Calif), which is in turn plated and screened essentially as described by Sambrook et al., (Molecular Cloning) with oligonucleotide (5'-CTTCAACTGC ACATACCCTC CAGTAACAAA CGGGGCAGTG AATCTGACAT-3') (Sequence I.D. No. 6). This oligonucleotide is complementary to nucleotides 211-260 of the rat IL-l Type 3 receptor cDNA sequence shown in Sequence I.D. No. 3.
  • the phage library is rescreened until a single pure phage isolate is obtained.
  • the phage is then grown on bacterial host XL 1 -Blue (Stratagene, LaJolla, Calif), and plasmid DNA is excised with ExAssist helper phage (Stratagene) in SOLR cells.
  • the SOLR cells are then plated, and plasmid DNA is isolated and sequenced utilizing the Sanger dideoxy protocol.
  • a rat IL-l Type 3 receptor cDNA sequence that may be obtained utilizing this procedure is set forth in Sequence I.D. No. 3.
  • IL-l Type 3 receptor cDNA can also be isolated from commercially available rat cDNA libraries. For example, two million plaques from a rat phage library
  • a rat IL-l Type 3 receptor cDNA sequence that may be obtained utilizing this procedure is set forth in Sequence I.D. No.3.
  • IL-l Type 3 receptor cDNA can also be isolated from commercially available human cDNA libraries. Briefly, approximately two million plaques from a human phage library (Clontech, catalog # HL1 158a) are plated according to the manufacturers instructions, and screened with oligonucleotide (5'-CCTCCCATAA
  • This oligonucleotide is complementary to nucleotides 260-310 of the human IL-l Type 3 receptor cDNA sequence shown in Sequence I.D. No. 1.
  • the phage library is rescreened and isolated as described above.
  • the human sequence that is obtained utilizing this procedure is approximately 89.1% identical at the nucleotide level and 89.2% identical at the amino acid level to that of the common region of the above-described rat IL-l Type 3 receptors.
  • pCDM7amp is a DNA plasmid which contains 1) an ampicillin resistance gene that provides for selection in prokaryotic cells, 2) a bacterial origin of replication which allows propagation and amplification in host bacterial cells, 3) a CMV (cytomegalovirus) promoter which sponsors transcription in mammalian cells, 4) a multiple cloning site (MCS), which is a series of adjacent restriction sites in the DNA sequence that are useful for the insertion of appropriate DNA fragments, and 5) a SV 40 T-antigen splice and polyadenylation site.
  • pCDM7-Amp is constructed from pCDM8 (Seed, Nature 329:840-842,
  • a full-length rat IL-l Type 3 receptor clone in pBluescriptSK- is isolated from the phage clone described above, and cut with EcoRV and Hindlll, releasing two inserts. The inserts are then isolated and ligated to pCDM7-Amp which had been similarly cut. The resulting product is used to transform E. coli DH5 ⁇ , and colonies are examined by restriction digests for correct orientation of the two inserts (i.e., proper formation of the IL-l Type 3R coding sequence.) COS-7 (ATCC No. CRL 1651) cells are then transfected with pCDM7-
  • IL-l Type 3 receptor cDNA (10 ug DNA/ 10 cm plate of cells) utilizing 400 ⁇ g/ml of DEAE-Dextran and 100 ⁇ M chloroquine.
  • the cells are transfected for 4 hours, then shocked with 10% DMSO for 2 minutes.
  • the cells are then washed, and grown in DMEM containing 10% Fetal Bovine Serum for 2 days in a 24-well plate.
  • COS-7 (ATCC No. CRL 1651) cells are then transfected with pCDM7- A p containing IL-l Type 3 receptor cDNA (10 ug DNA 10 cm plate of cells) utilizing 400 ⁇ g/ml of DEAE-Dextran and 100 ⁇ M chloroquine. The cells are transfected for 4 hours, then shocked with 10% DMSO for 2 minutes. The cells are then washed, and grown in DMEM containing 10% Fetal Bovine Serum for 2 days in a 24-well plate.
  • 1 type 3 receptor also referred to as the "soluble" form of the receptor, is constructed essentially as described below.
  • pCDM7amp DNA (as described above) is subjected to restriction endonuclease digestion with two enzymes, Notl and Xhol, each of which have one recognition site in this vector, both located in the MCS.
  • the product is a linearized DNA fragment with the CMV promoter/enhancer immediately upstream of the cut site, and the polyadenylation signal downstream of the cut site.
  • the cleaved vector is isolated by agarose gel electrophoresis and purified using the Gene Clean procedure (Bio 101, San Diego, CA). The vector is now ready to combine with a DNA fragment encoding the soluble human IL-l type 3 receptors.
  • the first primer consists of the sequence 5'-CCTACTCGAG ATGTGGTCCT TGCTGCTC-3' (Sequence ID No: 8).
  • the first four nucleotides of this sequence serve as a spacer, and increase the efficiency of endonuclease cleavage in a subsequent reaction to be described.
  • Nucleotides 5 through 10 encode a Xhol endonuclease cleavage site, and nucleotides 1 1 through 28 are identical to the N-terminal coding region of the human IL-type 3 receptor (nucleotides 129 to 146 in Sequence ID No: 1)).
  • the second primer consists of the sequence 5'-ATGCGCGGCC GCCTATCGAA AATCCGGAGC TGG-3' (Sequence Id No: 9).
  • the first four nucleotides of this sequence serve as a spacer, and increase efficiency of endonuclease cleavage in a subsequent reaction to be described.
  • Nucleotides 5 through 12 encode a No/I endonuclease cleavage site.
  • Nucleotides 13 through 15 encode a translation stop codon, and nucleotides 16 though 33 are complementary to the coding region of the human IL-l type 3 receptor immediately preceding the transmembrane region (nucleotides 1133 through 11 16 in Sequence ID No. 1).
  • the fragment encoding soluble human IL-l type 3 receptor is then generated by PCR. Briefly, lOOng of each primer are combined in a 0.5ml test tube, along with lng of the entire human IL-l type 3 receptor DNA sequence contained in a cloning vector, such as Bluescript (Stratagene, La Jolla, CA). Ten microliters of 10X PCR buffer, 5ul of 25mM MgCl, lul of 25mM aTP, and lul of Taq polymerase/Vent polymerase (16: 1 ratio) are also added to the reaction. The complete sample is then overlayed with lOOul of mineral oil to prevent evaporation, and the sample is placed in a thermocycler.
  • a cloning vector such as Bluescript (Stratagene, La Jolla, CA).
  • Reaction conditions are: 94°C for 15 seconds, 55°C for 60 seconds, and 72°C for 60 seconds. These conditions are repeated for 25 cycles.
  • Product from the reaction is analyzed by agarose gel electrophoresis to verify the size of the fragment (1009 bp) and also to determine the approximate amount of DNA generated.
  • the DNA is then isolated by phenol/chloroform extraction and purified over a G-50 mini-spin column (Boehringer Mannheim, Indianapolis, IN) Approximately lOug of the purified DNA fragment is digested with 20 units each of Xhol and NotI restriction endonucleases in a standard reaction to generate cohesive ends on the fragment which are compatible with the pCDM7 vector prepared as detailed above.
  • the digested fragment is then agarose gel purified to remove impurities and contaminating DNA species.
  • One hundred nanograms of vector DNA is combined with lOOng of insert DNA in a 1.5ml mini-tube with lul of 10X ligation buffer, lul of DNA ligase (Boehringer Mannheim), and water to a total volume of lOul. This sample is incubated at 23°C for 2 hours.
  • Transformation One hundred microliters of competent E. coli bacteria cells are combined with the ligation product and incubated on ice for 30 minutes. The sample is then incubated at 42°C for 45 seconds. One milliliter of bacterial medium (Circle Grow, Bio 101, San Diego, CA) is then added, and the sample is shaken at 37°C for 60 minutes. The sample is then plated on a bacterial growth plate containing bacterial medium and ampicillin at lOOug/ml (Fisher Scientific), and incubated for 16 hours at 37°C.
  • Plasmid DNA is then extracted from the remaining cultures by the mini-prep procedure essentially as described by Maniatis et al. (supra), and the recovered DNAs are analyzed by restriction digest with Xhol and No/I restriction endonucleases. The products of restriction digest are visualized by agarose gel electrophoresis and ethidium bromide staining. Correct plasmids will yield two bands: a vector band of approximately 3 kilobases, and an insert fragment of 1009 bases.
  • the frozen stock of a colony containing the correct plasmid is used to inoculate one liter of bacterial growth medium containing ampicillin (lOOug ml).
  • the culture is shaken at 37°C for 24 hours, and plasmid D ⁇ A is isolated by a maxi-prep procedure (Promega).
  • the portion on this plasmid coding for soluble human IL-l type 3 receptor is analyzed by D ⁇ A sequencing (US Biochemical) in order to verify that the sequence is correct.
  • COS-7 (ATCC No. CRL 1651) or L-tk" cells (ATCC No. CCL 1.3 ) are seeded at lxlO 6 or 3xl0 6 cells on 10 cm tissue culture dishes and incubated over night. Cells are then transfected by a standard DEAE dextran method. Briefly, lO ⁇ g of IL-l type 3 receptor expression plasmid DNA are diluted in 3 ml of Dulbecco's modified Minimum Essential Medium (D-MEM) supplemented with glutamine, pyruvate, 25mM HEPES, 100 microgram/ml DEAE dextran (0.5 Md., Sigma, St. Louis) and 0.1 mM chloroquine (Sigma).
  • D-MEM Dulbecco's modified Minimum Essential Medium
  • IL-l type 1 receptor cDNA and type 3 receptor cDNA are separately transfected into Jurkat cells (ATCC no. TIB 152) together with a reporter plasmid consisting of the HIV promoter region (HIV-LTR) linked to the bacterial chloramphenicol acetyltransferase (CAT) gene. Stimulation of the transfected cells with human IL-l alpha leads through a signaling cascade involving the transcription factor NF-kappaB to the production of CAT, which in turn can be measured by commercially available assays (Promega, Madison, WI) (see also Leung et al., J. Biol. Chem. 269:1579-1582, 1994).
  • Results are shown in Figure 3. Briefly, approximately equal stimulation of CAT activity for both receptors can be seen over mock transfected control cells. This indicates that human IL-l alpha can signal through the IL-l type 3 receptor.
  • RNA protection assays are performed. Briefly, total 32 RNA is isolated from each tissue or part of the brain and annealed at 65°C to P- labeled RNA generated from a plasmid containing a 600 bp fragment which covers the entire transmembrane region and portions of the extracellular and intracellular domains of the Type 3 receptor cDNA. Samples are then digested with RNase and fractionated on a denaturing polyacrylamice gel. The gel is then dried and the radioactivity quantitated using a Phospholmager ( Figure 4).
  • the highest level of expression is in the lung, followed by the epididymus and testis.
  • the cerebral cortex contains the highest level of the Type 3 receptor, although other areas of the brain were also positive.
  • the IL-l type 3 receptor may be found in the thymus and the spleen. In the thymus the signal is most prominent in the cortical region and not in the medulla. Within the rat brain the IL-l type 3 receptor expression is detectable in the hippocampus and the fourth ventricle. This is in contrast to the localization of the IL-l type 1 receptor which is restricted to the dentate gyrus granule cells. Briefly, dissected tissue is frozen in isopentane cooled to -42°C and subsequently stored at -80°C prior to sectioning on a cryostat. Slide-mounted tissue sections are then stored at -80°C.
  • Sections are removed from storage and placed directly into 4% buffered paraformaldehyde at room temperature. After 60 minutes, slides are rinsed in isotonic phosphate buffered saline (10 min.) and treated with proteinase K (1 ⁇ g/ml in 100 mM Tris/HCl, pH 8.0) for 10 minutes at 37°C. Subsequently, sections are successively washed in water (1 min.), 0.1 M triethanolamine (pH 8.0, plus 0.25% acetic anhydride) for 10 minutes and 2X SSC (0.3 mM NaCl, 0.03 mM sodium citrate, pH 7.2) for 5 minutes. Sections are then dehydrated through graded alcohols and air dried.
  • Post-fixed sections are hybridized with 1.0 x IO 6 dpm [35S]UTP-labeled riboprobes in hybridization buffer containing 75% formamide, 10% dextran sulphate, 3X SSC, 50 mM sodium phosphate buffer pH 7.4), IX Denhardt's solution, 0.1 mg/ml yeast tRNA and 10 mM dithiothreitol in a total volume of 30 ⁇ l.
  • the diluted probe is applied to sections on a glass coverslip and hybridized overnight at 55°C in a humid environment.
  • sections Post-hybridization, sections are washed in 2X SSC for 5 minutes and then treated with RNase A (200 ⁇ g/ml in lO mM Tris/HCl, pH 8.0, containing 0.5 M NaCl) for 60 minutes at 37°C. Subsequently, sections are washed in 2X SSC for 5 minutes, IX SSC for 5 minutes, 0.1X SSC for 60 minutes at 70°C, 0.5X SSC at room temperature for 5 minutes and then dehydrated in graded alcohols and air dried. For signal detection, sections are placed on Kodak Bio Max X-ray film and exposed for the required length of time or dipped in photographic emulsion (Amsersham LM-1) for high resolution analysis. Autoradiograms are analyzed using automated image analysis (DAGE camera/Mac II) while dipped sections were examined using a Zeiss Axioscope.
  • RNase A 200 ⁇ g/ml in lO mM Tris/HCl, pH 8.0,
  • T lymphocyte lectins such as phytohemagglutin (PHA)
  • PHA phytohemagglutin
  • Soluble human Type 1 receptor produced in baculovirus may be used as a positive control.
  • soluble IL-l type 1 or type 3 receptors are added to wells of a 96 well plate and serially diluted IL-l is also added.
  • Thymi are removed from young mice and a single cell suspension prepared in tissue culture media. Cells are washed 3 times and resuspended at a concentration of 10 7 cells/ml. Cells are plated at 100 microliters in a 96 well flat bottom microtiter plate. PHA is added to stimulate the cells. Plates are then incubated for 48 hours in a 37°C, 5% CO 2 humidified incubator, and [ 3 H] thymidine is added to the cells for the last 4 to 6 hours. Cells are then harvested and the [ 3 H] thymidine inco ⁇ oration determined by liquid scintillation counting.
  • both human IL-l type 3 and rat IL-l type 3 receptors effectively inhibit thymocyte proliferation in a manner similar to that observed for soluble human type 1 receptor. This result strongly indicates that the type 3 receptor inhibits thymocyte proliferation by binding to the exogenously added IL-l.
  • ATC CCA GTG TCC AAA ATC ATA CAG TCT AGA A ⁇ CAC CAG GAC GAG ACT 362 H e Pro Val Ser Lys H e H e Gi n Ser Arg H e Hi s Gi n Asp Gl u Thr 65 70 75
  • GAT GAT TAC TAT GAT GAA TCC AAA CGA ATC AGA GAA GGG GTG GAA ACC 986 Asp Asp Tyr Tyr Asp Glu Ser Lys Arg He Arg Glu Gly Val Glu Thr 275 280 285
  • CAG GCC CAG AAC TAGGCTCAAG AAGAAAGAAG TGTACTCTCA CGACTGGCTA 1854 Gin Ala Gin Asn 560
  • MOLECULE TYPE protein
  • TGTACAGCTC CACTTGGGGA AGCCCGAA ATG GGG ATG CCA CCC TTG CTC TTC 112
  • TGT TAC CGA ATA GCT ATA AAC CTA ACC GTT TTT AGA AAA CAC TGG TGC 448 Cys Tyr Arg He Ala He Asn Leu Thr Val Phe Arg Lys His Trp Cys 105 110 115 120
  • ACG TAT CCA AAA AAC AAC TCC ATT GAA GTT CAA C ⁇ GGC TCC ACC CTC 832 Thr Tyr Pro Lys Asn Asn Ser He Glu Val Gin Leu Gly Ser Thr Leu 235 240 245
  • CAG TAC ATC CGA CAG AAG CAC GGG GCC ATC CAG TGG GAT GGG GAC TTC 1648 Gin Tyr He Arg Gin Lys His Gly Ala He Gin Trp Asp Gly Asp Phe 505 510 515 520

Abstract

The present invention provides isolated nucleic acid molecules encoding soluble and membrane bound forms of Interleukin-1 Type 3 receptors, as well as recombinant expression vectors and host cells suitable for expressing such receptors.

Description

Description
INTERLEUKΓN-1 TYPE3RECEPTORS
Technical Field
The present invention relates generally to cell surface receptors, and more specifically, to Interleukin-1 Type 3 receptors.
Background Of The Invention Interleukin- 1 ("IL-1 ") is a cytokine which is known to be a key mediator of immunological and pathological responses to stress, infection and antigenic challenge (Oppenheim et al., Immunol. Today 7:45-46, 1986; Dinarello, FASEB J. 2: 108-1 15, 1988; and Mizel, FASEB J. 3:2379-2388, 1989). In addition, IL-1 is known to have a variety of effects on the brain and central nervous system. For example, IL-1 has been postulated to be involved in the induction of fever (Kluger, Physiol. Rev. 77:93-127, 1991), increased duration of slow wave sleep (Opp et al., Am. J. Physiol. 260:R52-R58, 1991), decreased appetite (McCarthy et al., Am. J. Clin. Nutr. ^2: 1179-1182, 1985), activation of the hypothalamic-pituitary-adrenal ("HP A") axis (Woloski et al., Science 230: 1035-1037, 1985), and inhibition of the hypothalamic-pituitary-gonadal axis (River and Vale, Endocrinology 124:2105-2109, 1989).
In light of the above-noted effects of IL-1 (as well as many others), substantial effort has been undertaken in order to identify receptors for IL-1. Briefly, at least two types of receptors are known to be expressed on the surface of certain immune cells in both human and murine derived lines. Type I receptors bind both IL-lα and IL-lβ, and can be found on T cells, fibroblasts, keratinocytes, endothelial cells, synovial lining cells, chondrocytes and hepatocytes (U.S. Patent Nos. 4,968,607, 5,081,228, and 5,180,812; Chizzonite et al., PNAS 56:8029-8033, 1989; Dinarello et al., Blood 77:1627-1652, 1991). Type II receptors can be found on various B cell lines, including the Raji human B-cell lymphoma line (Bomsztyk et al., PNAS 56:8034-8038, 1989; Horuk et al., J. Biol. Chem. 262:16275-16278, 1987; Horuk and McCubrey, Biochem. J. 260:657-663, 1989).
The present invention provides new, previously unidentified Interleukin receptors, designated Interleukin- 1 Type 3 receptors ("IL-I R"). In addition, the present invention provides compositions and methods which utilize such receptors, as well as other, related advantages. Summary of the Invention
Briefly stated, the present invention provides compositions and methods which comprise Interleukin- 1 Type 3 receptors. Within one aspect of the present invention isolated nucleic acid molecules are provided which encode Interleukin- 1 Type 3 receptors. Within one embodiment, the isolated nucleic acid molecules comprise the sequence of nucleotides in Sequence I.D. No. 1, from nucleotide number 129 to nucleotide number 1814. Within another embodiment, the isolated nucleic acid molecules encode a protein having the amino acid sequence of Sequence I.D. No. 2, from amino acid number 1 to amino acid number 562. Within other embodiments, isolated nucleic acid molecules are provided in Sequence I.D. No. 3, from nucleotide number 89 to nucleotide number 1771. Within another embodiment, the nucleic acid molecules encode a protein having the amino acid sequence of Sequence I.D. No. 4, from amino acid number 1 to amino acid number 561. Nucleic acid molecules which encode IL-1 Type 3 receptors of the present invention may be isolated from virtually any warm-blooded animal, including for example, humans, macaques, horses, cattle, sheep, pigs, dogs, cats, rats and mice.
Within related aspects of the present invention, isolated nucleic acid molecules are provided which encode soluble Interleukin- 1 Type 3 receptors. Within one embodiment, the isolated nucleic acid molecules comprise the sequence of nucleotides in Sequence I.D. No. 1, from nucleotide number 129 to nucleotide number 1136. Within other embodiments, the isolated nucleic acid molecules encode a protein having the amino acid sequence of Sequence I.D. No. 2, from amino acid number 1 to amino acid number 336. Within another embodiment, the nucleic acid molecules comprise the sequence of nucleotides in Sequence I.D. No. 3, from nucleotide number 89 to nucleotide number 1102. Within yet another embodiment, the nucleic acid molecules encode a protein having the amino acid sequence of Sequence I.D. No. 4, from amino acid number 1 to amino acid number 338. As above, nucleic acid molecules which encode soluble IL-1 Type 3 receptors of the present invention may be isolated from virtually any warm-blooded animal, including for example, humans, macaques, horses, cattle, sheep, pigs, dogs, cats, rats and mice.
Within other aspects of the present invention, expression vectors are provided which are capable of expressing the above-described nucleic acid molecules. Within one embodiment, such vectors comprise a promoter operably linked to one of the above-described nucleic acid molecules. Within other embodiments, recombinant viral vectors are provided which are capable of directing the expression of one of the above described nucleic acid molecules. Representative examples of such viral vectors include retroviral vectors, adenoviral vectors, and heφes simplex virus vectors. Also provided by the present invention are host cells containing one of the above-described recombinant vectors.
Within other aspects of the present invention, isolated Interleukin- 1 Type 3 receptors are provided. Within one embodiment, such receptors have the amino acid sequence of Sequence I.D. No. 2, from amino acid number 1 to amino acid number 562. Within another embodiment, the receptors have the sequence of Sequence I.D. No. 4, from amino acid number 1 to amino acid number 561. Within yet further aspects of the invention, isolated soluble Interleukin- 1 Type 3 receptors are provided. Within one embodiment, the isolated soluble Interleukin- 1 Type 3 receptors have the amino acid sequence of Sequence I.D. No. 2, from amino acid number 1 to amino acid number 336. Within another embodiment, the soluble receptors have the sequence of Sequence I.D. No. 4, from amino acid number 1 to amino acid number 338.
Within other aspects of the invention, isolated antibodies capable of specifically binding to an Interleukin- 1 Type 3 receptor are provided. Within one embodiment, the antibody may be selected from the group consisting of polyclonal antibodies, monoclonal antibodies, and antibody fragments. Within other embodiments, antibodies are provided which are capable of blocking the binding of IL-1 to an Interleukin- 1 Type 3 receptor. Within preferred embodiments, the antibody is selected from the group consisting of murine and human antibodies. In addition to antibodies, the present invention also provides hybridomas which produces an antibody as described above.
Within yet another aspect of the present invention, nucleic acid molecules are provided which are capable of specifically hybridizing to a nucleic acid molecule encoding any of the Interleukin- 1 Type 3 receptors described above. Such molecules may be between at least "y" nucleotides long, wherein "y" is any integer between 14 and 2044, and furthermore, may be selected suitable for use as probes or primers described below. Particularly preferred probes of the present invention are at least 18 nucleotides in length.
These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth below which describe in more detail certain procedures or compositions (e.g., plasmids, etc.), and are therefore incoφorated by reference in their entirety.
Brief Description of the Drawings
Figure 1 schematically illustrates a rat IL-1 type 3 receptor. Figure 2 is a table which lists the homology of a human IL-1 type 3 receptor with its rat homologue, and other interleukin receptors.
Figure 3 is a graph which shows stimulation of a reporter product via a human IL-1 type 3 receptor. Figure 4 is a graph which shows the expression pattern of the IL-1 Type
3 receptor based upon RNA protection assays.
Figures 5 A and B are two graphs wh ich show inhibition of thymocyte proliferation by soluble IL-1 receptors.z
Detailed Description of the Invention Definitions
Prior to setting forth the invention, it may be helpful to an understanding thereof to set forth definitions of certain terms to be used hereinafter.
"Interleukin- 1 Type 3 Receptors" ("IL-1-3R") refers to receptor proteins which bind Interleukin- 1 (α or β), and, when expressed on a cell surface, transduce the signal provided by Interleukin- 1 to the cell, thereby mediating a biological effect within the cell. In their native configuration, IL-1 Type 3 receptors exist as membrane bound proteins, consisting of an extracellular domain, transmembrane domain, and intracellular domain (see Figure 1). IL-1-3R may be distinguished from other Interleukin-1 receptors based upon criteria such as affinity of substrate binding, tissue distribution, and sequence homology. For example, IL-1-3R of the present invention should be greater than 50% homologous, preferably greater than 75% to 80% homologous, more preferably greater than 85% to 90% homologous, and most preferably greater than 92%, 95%, or 97% homologous to the IL-1-3R disclosed herein (e.g., Sequence I.D. No. 1). As utilized within the context of the present invention, IL1-3R should be understood to include not only the proteins which are disclosed herein, but substantially similar derivatives and analogs as discussed below.
"Soluble Interleukin- 1 Type 3 Receptor" ("sILl-3R") refers to a protein which has an amino acid sequence corresponding to the extracellular region of an Interleukin- 1 Type 3 receptor. The extracellular region of IL-1-3R may be readily determined by a hydrophobicity analysis utilizing a computer program such as PROTEAN (DNASTAR, Madison, WI), or by an alignment analysis with other known type 1 and type 2 Interleukin- 1 receptors.
"Nucleic acid molecule" refers to a nucleic acid polymer or nucleic acid sequence, which exists in the form of a separate fragment or as a component of a larger nucleic acid construct. The nucleic acid molecule must have been derived from nucleic acids isolated at least once in substantially pure form, (i.e., substantially free of contaminating endogenous materials), and in a quantity or concentration enabling identification and recovery. Such sequences are preferably provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns. As utilized herein, nucleic acid molecules should be understood to include deoxyribonucleic acid ("DNA") molecules (including genomic and cDNA molecules), ribonucleic acid ("RNA") molecules, hybrid or chimeric nucleic acid molecules (e.g., DNA-RNA hybrids), and where appropriate, nucleic acid molecule analogs and derivatives (e.g., peptide nucleic acids ("PNA")). Nucleic acid molecules of the present invention may also comprise sequences of non-translated nucleic acids where such additional sequences do not interfere with manipulation or expression of the open reading frame (e.g., sequences which are 5' or 3' from the open reading frame).
"Recombinant expression vector" refers to a replicable nucleic acid construct used either to amplify or to express nucleic acid sequences which encode IL-1 Type 3, or sIL-1 Type 3 receptors. This construct comprises an assembly of (l) a genetic element or elements having a regulatory role in gene expression, for example, promoters, and (2) the structural or coding sequence of interest. The recombinant expression vector may also comprise appropriate transcription and translation initiation and termination sequences.
As noted above, the present invention provides isolated nucleic acid molecules encoding Interleukin- 1 Type 3 receptors. One representative IL-1 Type 3 receptor which may be obtained utilizing the methods described herein (see, e.g., Example 1) is schematically illustrated in Figure 1. Briefly, this IL-1 Type 3 receptor (see Sequence I.D. Nos. 1 and 2) is composed of an Extracellular N-terminal Domain (amino acids 1 - 336), a Transmembrane Domain (amino acids 337 - 357), and a C-terminal Intracellular Domain (358 - 562).
Although the above IL-1 Type 3 receptor has been provided for puφoses of illustration (see also Sequence I.D. Nos. 3 and 4), the present invention should not be so limited. In particular, "IL-1-3R" and "sIL-l-3R" as utilized herein should be understood to include a wide variety of IL-1 Type 3 receptors which are encoded by nucleic acid molecules that have substantial similarity to the sequences disclosed in Sequences I.D. Nos. 1 and 3. As utilized within the context of the present invention, nucleic acid molecules which encode IL-1 Type 3 receptors are deemed to be substantially similar to those disclosed herein if: (a) the nucleic acid sequence is derived from the coding region of a native IL-1 Type 3 receptor gene (including, for example, allelic variations of the sequences disclosed herein); (b) the nucleic acid sequence is capable of hybridization to nucleic acid sequences of the present invention under conditions of either moderate (e.g., 50% formamide, 5 x SSPE, 5 x Denhardt's, 0.1% SDS, 100 ug/ml Salmon Sperm DNA, and a temperature of 42°C) or high stringency (see Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, NY, 1989); or (c) nucleic acid sequences are degenerate as a result of the genetic code to the nucleic acid sequences de ined in (a) or (b). Furthermore, as noted above, although DNA molecules are primarily referred to herein, as should be evident to one of skill in the art given the disclosure provided herein, a wide variety of related nucleic acid molecules may also be utilized in various embodiments described herein, including for example, RNA, nucleic acid analogues, as well as chimeric nucleic acid molecules which may be composed of more than one type of nucleic acid.
In addition, as noted above, within the context of the present invention "IL-1 Type 3 receptors" and "soluble IL-1 Type 3 receptors" should be understood to include derivatives and analogs of the IL-1 Type 3 receptors described above. Such derivatives include allelic variants and genetically engineered variants that contain conservative amino acid substitutions and/or minor additions, substitutions or deletions of amino acids, the net effect of which does not substantially change the biological activity (e.g., signal transduction) or function of the IL-1 Type 3 receptor. Such derivatives are generally greater than about 50% homologous, preferably greater than 75% to 80% homologous, more preferably greater than 85% to 90% homologous, and most preferably greater than 92%, 95% or 97% homologous. Homology may be determined, for example, by comparing sequence information using the GAP computer program, version 6.0, available from the University of Wisconsin Genetics Computer Group (UWGCG). The primary amino acid structure of IL-1 Type 3 receptors may also be modified by derivatizing amino acid side chains, and/or the amino or carboxy termus with various functional groups, in order to allow for the formation of various conjugates (e.g., protein-IL-l-3R conjugates). Alternatively, conjugates of IL-1-3R (and sIL-l-3R) may be constructed by recombinantly producing fusion proteins. Such fusion proteins may comprise, for example, IL-l-3R-protein Z wherein protein Z is another cytokine receptor (e.g., IL-2R, IL-3R, IL-4R, IL-5R, 1L-6R, IL-7R, IL-8R, IL-9R, IL-10R, E_- 11R, IL-12R, IL-13R, IL-14R, IL-15R or TNF (α or β) receptor; see WO91/03553); a binding portion of an antibody; a toxin (as discussed below); or a protein or peptide which facilitates purification or identification of IL-1-3R (e.g., poly-His). For example, a fusion protein such as human IL-1 -3R (His)n or sIL-l-3R (His)n may be constructed in order to allow purification of the protein via the poly-His residue, for example, on a NTA nickel-chelating column. The amino acid sequence of a IL-1 Type 3 receptor may also be linked to the peptide Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (DYKDDDDK) (Sequence I.D. No. 5) (Hopp et al., Bio/Technology 6: 1204, 1988) in order to facilitate purification of expressed recombinant protein.
The present invention also includes IL-1-3R (and sIL-l-3R) proteins which may be produced either with or without associated native-pattern glycosylation. For example, expression of EL-1-3R DNAs in bacteria such as E. coli provides non- glycosylated molecules. In contrast, IL-1-3R expressed in yeast or mammalian expression systems (as discussed below) may vary in both glycosylation pattern and molecular weight from native EL-1-3R, depending on the amino acid sequence and expression system which is utilized. In addition, functional mutants of mammalian IL-1- 3R having inactivated glycosylation sites may also be produced in a homogeneous, reduced-carbohydrate form, utilizing oligonucleotide synthesis, site-directed mutagenesis, or random mutagenesis techniques. Briefly, N-glycosylation sites in eukaryotic proteins are generally characterized by the amino acid triplet Asn-Aj-Z, where Aι is any amino acid except Pro, and Z is Ser or Thr. In this triplet, asparagine provides a side chain amino group for covalent attachment of carbohydrate. Such sites may be eliminated by deleting Asn or Z, substituting another amino acid for Asn or for residue Z, or inserting a non-Z amino acid between Aj and Z, or an amino acid other than Asn between Asn and Aj. Proteins which are substantially similar to IL-1-3R proteins may also be constructed by, for example, substituting or deleting various amino acid residues which are not required for biological activity. For example, cysteine residues may be deleted or replaced with other amino acids to prevent formation of incorrect intramolecular disulfide bridges upon renaturation. Similarly, adjacent dibasic amino acid residues may be modified for expression in yeast systems in which KEX2 protease activity is present.
Not all mutations in the nucleotide sequence which encodes IL-1-3R will be expressed in the final product. For example, nucleotide substitutions may be made in order to avoid secondary structure loops in the transcribed mRNA, or to provide codons that are more readily translated by the selected host, and thereby enhance expression within a selected host.
Generally, substitutions at the amino acid level should be made conservatively, i.e., the most preferred substitute amino acids are those which have characteristics resembling those of the residue to be replaced. When a substitution, deletion, or insertion strategy is adopted, the potential effect of the deletion or insertion on biological activity should be considered utilizing, for example, the signalling assay disclosed within the Examples. Mutations which are made to the sequence of the nucleic acid molecules of the present invention should generally preserve the reading frame phase of the coding sequences. Furthermore, the mutations should preferably not create complementary regions that could hybridize to produce secondary mRNA structures, such as loops or haiφins, which would adversely affect translation of the receptor mRNA. Although a mutation site may be predetermined, it is not necessary that the nature of the mutation per se be predetermined. For example, in order to select for optimum characteristics of mutants at a given site, random mutagenesis may be conducted at the target codon, and the expressed IL-1-3R mutants screened for the biological activity. Representative methods for random mutagenesis include those described by Ladner et al. in U.S. Patent Nos. 5,096,815; 5,198,346; and 5,223,409.
As noted above, mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion.
Alternatively, site-directed mutagenesis procedures may be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Exemplary methods of making the alterations set forth above are disclosed by Walder et al. (Gene 42Λ33, 1986); Bauer et al. (Gene 37:73, 1985); Craik, Bio Techniques, January 1985, 12-19); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press, 1981); Sambrook et al. (Molecular cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, 1989); and U.S. Patent Nos. 4,518,584 and 4,737,462, which are incoφorated by reference herein. IL-1 Type 3 receptors, as well as substantially similar derivatives or analogs may be used as therapeutic reagents, immunogens, reagents in receptor-based immunoassays, or as binding agents for affinity purification procedures. Moreover, IL-1 Type 3 receptors of the present invention may be utilized to screen compounds for IL-1 Type 3 receptor agonist or antagonistic activity. IL-1 Type 3 receptor proteins may also be covalently bound through reactive side groups to various insoluble substrates, such as cyanogen bromine-activated, bisoxirane-activated, carbonyldiimidazole-activated, or tosyl-activated, agarose structures, or by adsorbing to polyolefin surfaces (with or without glutaraldehyde cross-linking). Once bound to a substrate, IL-1-3R may be used to selectively bind (for puφoses of assay or purification) anti-IL-l-3R antibodies or IL- 1. ISOLATION OF JX-1 TYPE 3 RECEPTOR CDNA CLONES As noted above, the present invention provides isolated nucleic acid molecules which encode IL-1 Type 3 receptors. Briefly, nucleic acid molecules which encode IL-1 Type 3 receptors of the present invention may be readily isolated from a variety of warm-blooded animals, including for example, humans, macaques, horses, cattle, sheep, pigs, dogs, cats, rats and mice. Particularly preferred tissues from which nucleic acid molecules which encode IL-1 Type 3 receptors may be isolated include brain, kidney and lung. Nucleic acid molecules which encode IL-1 Type 3 receptors of the present invention may be readily isolated from conventionally prepared cDNA libraries (see, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, NY, 1989) or from commercially obtained libraries (e.g., Stratagene, LaJolla, Calif.) utilizing the disclosure provided herein. Particularly preferred methods for obtaining isolated DNA molecules which encode EL-1 Type 3 receptors of the present invention are described in more detail below in Example 1 (see also Sequence I.D. Nos. 1 and 3).
As noted above, within particularly preferred embodiments of the invention, isolated nucleic acid molecules are provided which encode human EL-1 Type 3 receptors. Briefly, such nucleic acid molecules may be readily obtained by probing a human cDNA library either with a specific sequence as described below in Example 1, or with a rat sequence (e.g.. Sequence I.D. Nos. 2 or 4) under conditions of high stringency (e.g., 50% formamide, 5 x SSC, 5x Denharts, 0.1% SDS, 100 ug/ml salmon sperm DNA, at 42°C for 12 hours). This may be followed by extensive washing with 2x SSC containing 0.2% SDS at 50°C. Suitable cDNA libraries may be obtained from commercial sources (e.g., Stratagene, LaJolla, Calif; or Clontech, Palo Alto, Calif, or prepared utilizing standard techniques (see, e.g,. Sambrook et al., supra).
PRODUCTION OF RECOMBINANT IL-l TYPE 3 RECEPTORS As noted above, the present invention also provides recombinant expression vectors which include synthetic or cDNA-derived DNA fragments encoding IL-l Type 3 receptors or substantially similar proteins, which are operably linked to suitable transcriptional or translation regulatory elements derived from mammalian, microbial, viral or insect genes. Such regulatory elements include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites, and, within preferred embodiments, sequences which control the termination of transcription and translation. The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants may additionally be incoφorated. DNA regions are operably linked when they are functionally related to each other. For example, DNA for a signal peptide (secretory leader) is operably linked to DNA for a polypeptide if it is expressed as a precursor which participates in the secretion of the polypeptide; a promoter is operably linked to a coding sequence if it controls the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation. Generally, operably linked means contiguous and, in the case of secretory leaders, contiguous and in reading frame.
Expression vectors may also contain DNA sequences necessary to direct the secretion of a polypeptide of interest. Such DNA sequences may include at least one secretory signal sequence. Representative secretory signals include the alpha factor signal sequence (pre-pro sequence; Kurjan and Herskowitz, Cell 30:933-943, 1982; Kurjan et al., U.S. Patent No. 4,546,082; Brake, EP 1 16,201), the PHO5 signal sequence (Beck et al., WO 86/00637), the BAR1 secretory signal sequence (MacKay et al., U.S. Patent No. 4,613,572; MacKay, WO 87/002670), the SUC2 signal sequence (Carlson et al., Mol. Cell. Biol. 3:439-447, 1983), the α-1-antitrypsin signal sequence (Kurachi et al., Proc. Natl. Acad. Sci. USA 75:6826-6830, 1981), the β-2 plasmin inhibitor signal sequence (Tone et al., J. Biochem. (Tokyo) J 02:1033-1042, 1987), the tissue plasminogen activator signal sequence (Pennica et al., Nature 307:214-221, 1983), the E. coli PhoA signal sequence (Yuan et al., J. Biol. Chem. 265:13528-13552, 1990) or any of the bacterial signal sequences reviewed, for example, by Oliver (Ann. Rev. Microbiol. 39:615-649, 1985). Alternatively, a secretory signal sequence may be synthesized according to the rules established, for example, by von Heinje (Eur. J. Biochem. 733: 17-21, 1983; J. Mol. Biol. 75 99-105, 1985; Nuc. Acids Res. 7 4683- 4690, 1986). For expression, a nucleic acid molecule encoding a IL-l Type 3 receptor is inserted into a suitable expression vector, which in turn is used to transform or transfect appropriate host cells for expression. Host cells for use in practicing the present invention include mammalian, avian, plant, insect, bacterial and fungal cells. Preferred eukaryotic cells include cultured mammalian cell lines (e.g., rodent or human cell lines) and fungal cells, including species of yeast (e.g., Saccharomyces spp., particularly S. cerevisiae, Schizosaccharomyces spp., or Kluyveromyces spp.) or filamentous fungi (e.g., Aspergillus spp., Neurospora spp.). Strains of the yeast Saccharomyces cerevisiae are particularly preferred. Methods for producing recombinant proteins in a variety of prokaryotic and eukaryotic host cells are generally known in the art (see "Gene Expression Technology," Methods in Enzymology, Vol. 185, Goeddel (ed.), Academic Press, San Diego, Calif, 1990; see also, "Guide to Yeast Genetics and Molecular Biology," Methods in Enzymology, Guthrie and Fink (eds.) Academic Press, San Diego, Calif, 1991). In general, a host cell will be selected on the basis of its ability to produce the protein of interest at a high level or its ability to carry out at least some of the processing steps necessary for the biological activity of the protein. In this way, the number of cloned DNA sequences which must be transfected into the host cell may be minimized and overall yield of biologically active protein may be maximized.
Suitable yeast vectors for use in the present invention include YRp7 (Struhl et al., Proc. Natl. Acad. Sci. USA 76:1035-1039, 1978), YEpl3 (Broach et al., Gene 5: 121-133, 1979), POT vectors (Kawasaki et al., U.S. Patent No. 4,931,373, which is incoφorated by reference herein), pJDB249 and pJDB219 (Beggs, Nature 275: 104-108, 1978) and derivatives thereof. Such vectors will generally include a selectable marker, which may be one of any number of genes that exhibit a dominant phenotype for which a phenotypic assay exists to enable transformants to be selected. Preferred selectable markers are those that complement host cell auxotrophy, provide antibiotic resistance or enable a cell to utilize specific carbon sources, and include LEU2 (Broach et al., ibid.), URA3 (Botstein et al.. Gene 5: 17, 1979), HIS3 (Struhl et al., ibid.) or POT1 (Kawasaki et al., ibid). Another suitable selectable marker is the CAT gene, which confers chloramphenicol resistance on yeast cells.
Preferred promoters for use in yeast include promoters from yeast glycolytic genes (Hitzeman et al., J. Biol. Chem. 255: 12073-12080, 1980; Alber and Kawasaki, J. Mol. Appl. Genet. 7:419-434, 1982; Kawasaki, U.S. Patent No. 4,599,311) or alcohol dehydrogenase genes (Young et al., in Genetic Engineering of Microorganisms for Chemicals, Hollaender et al. (eds.), p. 355, Plenum, New York, 1982; Ammerer, Meth. Enzymol. 707: 192-201, 1983). In this regard, particularly preferred promoters are the TPI1 promoter (Kawasaki, U.S. Patent No. 4,599,311, 1986) and the ADH2-4C promoter (Russell et al., Nature 30*652-654, 1983; Irani and Kilgore, U.S. Patent Application Serial No. 07/784,653, which is incoφorated herein by reference). The expression units may also include a transcriptional terminator, such as the 77Y7 terminator (Alber and Kawasaki, ibid.). In addition to yeast, proteins of the present invention can be expressed in filamentous fungi, for example, strains of the fungi Aspergillus (McKnight et al., U.S. Patent No. 4,935,349, which is incoφorated herein by reference). Examples of useful promoters include those derived from Aspergillus nidulans glycolytic genes, such as the ADH3 promoter (McKnight et al., EMBOJ. *2093-2099, 1985) and the tpiA promoter. An example of a suitable terminator is the ADH3 terminator (McKnight et al., ibid., 1985). The expression units utilizing such components are cloned into vectors that are capable of insertion into the chromosomal DNA of Aspergillus. Techniques for transforming fungi are well known in the literature, and have been described, for instance, by Beggs (ibid), Hinnen et al (Proc. Natl. Acad. Sci. USA 75 1929-1933, 1978), Yelton et al (Proc. Natl. Acad. Sci. USA 81 1740-1747, 1984), and Russell (Nature 301 167-169, 1983) The genotype of the host cell will generally contain a genetic defect that is complemented by the selectable marker present on the expression vector Choice of a particular host and selectable marker is well within the level of ordinary skill in the art To optimize production of the heterologous proteins in yeast, for example, it is preferred that the host strain carries a mutation, such as the yeast pep4 mutation (Jones, Genetics 85 23-33, 1977), which results in reduced proteolytic activity
In addition to fungal cells, cultured mammalian cells may be used as host cells within the present invention Preferred cultured mammalian cells for use in the present invention include the COS-1 (ATCC No CRL 1650), COS-7 (ATCC No CRL 1651), BHK (ATCC No CRL 1632), and 293 (ATCC No CRL 1573, Graham et al , J. Gen. Virol. 36 59-72, 1977) cell lines A preferred BHK cell line is the BHK 570 cell line (deposited with the American Type Culture Collection under accession number CRL 10314) In addition, a number of other mammalian cell lines may be used within the present invention, including Rat Hep I (ATCC No CRL 1600), Rat Hep II (ATCC No CRL 1548), TCMK (ATCC No CCL 139), Human lung (ATCC No CCL 75 1), Human hepatoma (ATCC No HTB-52), Hep G2 (ATCC No HB 8065), Mouse liver (ATCC No CCL 29 1), NCTC 1469 (ATCC No CCL 9 1), SP2/0-Agl4 (ATCC No 1581), HIT-T15 (ATCC No CRL 1777), Ltk- (ATCC) No CCL 1 3) and RINm 5AHT2B (Orskov and Nielson, FEBS 229(1) 175-178, 1988)
Mammalian expression vectors for use in carrying out the present invention should include a promoter capable of directing the transcription of a cloned gene or cDNA Preferred promoters include viral promoters and cellular promoters Viral promoters include the immediate early cytomegalovirus promoter (Boshart et al , Cell 41 521-530, 1985) and the SV40 promoter (Subramani et al , Mol Cell. Biol. 1 854-864, 1981) Cellular promoters include the mouse metallothionein-1 promoter (Palmiter et al., U S Patent No 4,579,821), a mouse Vj promoter (Bergman et al , Proc. Natl. Acad. Sci. USA 81 7041-7045, 1983, Grant et al , Nuc. Acids Res. 15 5496, 1987) and a mouse VH promoter (Loh et al , Cell 33 85-93, 1983) A particularly preferred promoter is the major late promoter from Adenovirus 2 (Kaufman and Shaφ, Mol. Cell. Biol. 2 1304-13199, 1982) Such expression vectors may also contain a set of RNA splice sites located downstream from the promoter and upstream from the DNA sequence encoding the peptide or protein of interest Preferred RNA splice sites may be obtained from SV40, adenovirus and/or immunoglobulin genes Alternatively, within certain embodiments RNA splice sites may be located downstream from the DNA sequence encoding the peptide or protein of interest. Also contained in the expression vectors is a polyadenylation signal located downstream of the coding sequence of interest. Suitable polyadenylation signals include the early or late polyadenylation signals from SV40 (Kaufman and Shaφ, ibid.), the polyadenylation signal from the Adenovirus 5 E1B region and the human growth hormone gene terminator (DeNoto et al., Nuc. Acids Res. 9:3719-3730, 1981). The expression vectors may include a noncoding viral leader sequence, such as the Adenovirus 2 tripartite leader, located between the promoter and the RNA splice sites. Preferred vectors may also include enhancer sequences, such as the SV40 enhancer and the mouse 1 enhancer (Gillies, Cell 33:717-728, 1983). Expression vectors may also include sequences encoding the adenovirus VA RNAs. Suitable vectors can be obtained from commercial sources (e.g., Invitrogen, San Diego, CA; Stratagene, La Jolla, CA).
Cloned DNA sequences may be introduced into cultured mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7:603, 1981; Graham and Van der Eb, Virology 52:456, 1973), electroporation (Neumann et al., EMBO J. 7:841-845, 1982), or DEAE-dextran mediated transfection (Ausubel et al. (eds ), Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987), which are incoφorated herein by reference. To identify cells that have stably integrated the cloned DNA, a selectable marker is generally introduced into the cells along with the gene or cDNA of interest. Preferred selectable markers for use in cultured mammalian cells include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate. The selectable marker may be an amplifiable selectable marker. Preferred amplifiable selectable markers are the DHFR gene and the neomycin resistance gene. Selectable markers are reviewed by Thilly (Mammalian Cell Technology, Butterworth Publishers, Stoneham, MA, which is incoφorated herein by reference). The choice of selectable markers is well within the level of ordinary skill in the art.
Selectable markers may be introduced into the cell on a separate vector at the same time as the IL-l Type 3 receptor sequence, or they may be introduced on the same vector. If on the same vector, the selectable marker and the IL-l Type 3 receptor sequence may be under the control of different promoters or the same promoter, the latter arrangement producing a dicistronic message. Constructs of this type are known in the art (for example, Levinson and Simonsen, U.S. Patent No. 4,713,339). It may also be advantageous to add additional DNA, known as "carrier DNA" to the mixture which is introduced into the cells. Transfected mammalian cells are allowed to grow for a period of time, typically 1-2 days, to begin expressing the DNA sequence(s) of interest. Drug selection is then applied to select for growth of cells that are expressing the selectable marker in a stable fashion. For cells that have been transfected with an amplifiable selectable marker the drug concentration may be increased in a stepwise manner to select for increased copy number of the cloned sequences, thereby increasing expression levels. Cells expressing the introduced sequences are selected and screened for production of the protein of interest in the desired form or at the desired level. Cells which satisfy these criteria may then be cloned and scaled up for production. Preferred prokaryotic host cells for use in carrying out the present invention are strains of the bacteria Escherichia coli, although Bacillus and other genera are also useful. Techniques for transforming these hosts and expressing foreign DNA sequences cloned therein are well known in the art (see, e.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 1982; or Sambrook et al., supra). Vectors used for expressing cloned DNA sequences in bacterial hosts will generally contain a selectable marker, such as a gene for antibiotic resistance, and a promoter that functions in the host cell. Appropriate promoters include the tφ (Nichols and Yanofsky, Meth. Enzymol. 707: 155-164, 1983), lac (Casadaban et al., J. Bacteriol. 7*3:971-980, 1980), and phage k (Queen, J. Mol. Appl. Genet. 2: 1-10, 1983) promoter systems. Plasmids useful for transforming bacteria include pBR322 (Bolivar et al., Gene 2:95-113, 1977), the pUC plasmids (Messing, Meth. Enzymol. 707:20-78, 1983; Vieira and Messing, Gene 79:259-268, 1982), pCQV2 (Queen, ibid , pMAL-2 (New England Biolabs, Beverly, MA) and derivatives thereof. Plasmids may contain both viral and bacterial elements. Given the teachings provided herein, promoters, terminators and methods for introducing expression vectors encoding IL-l Type 3 receptors of the present invention into plant, avian and insect cells would be evident to those of skill in the art. The use of baculoviruses, for example, as vectors for expressing heterologous DNA sequences in insect cells has been reviewed by Atkinson et al. (Pestic. Sci. 25:215- 224,1990). In addition, the use of Agrohacterium rhizogenes as vectors for expressing genes in plant cells has been reviewed by Sinkar et al. (J. Biosci. (Bangalore) 11 :47-58, 1987).
Host cells containing DNA molecules of the present invention are then cultured to express a DNA molecule encoding a IL-l Type 3 receptor. The cells are cultured according to standard methods in a culture medium containing nutrients required for growth of the chosen host cells. A variety of suitable media are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals, as well as other components, e.g., growth factors or serum, that may be required by the particular host cells. The growth medium will generally select for cells containing the DNA molecules by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker on the DNA construct or co-transfected with the DNA construct.
Suitable growth conditions for yeast cells, for example, include culturing in a chemically defined medium, comprising a nitrogen source, which may be a non- amino acid nitrogen source or a yeast extract, inorganic salts, vitamins and essential amino acid supplements at a temperature between 4°C and 37°C, with 30°C being particularly preferred. The pH of the medium is preferably maintained at a pH greater than 2 and less than 8, more preferably pH 5-6. Methods for maintaining a stable pH include buffering and constant pH control. Preferred agents for pH control include sodium hydroxide. Preferred buffering agents include succinic acid and Bis-Tris (Sigma Chemical Co., St. Louis, MO). Due to the tendency of yeast host cells to hyperglycosylate heterologous proteins, it may be preferable to express the IL-l Type 3 receptors of the present invention in yeast cells having a defect in a gene required for asparagine-linked glycosylation. Such cells are preferably grown in a medium containing an osmotic stabilizer. A preferred osmotic stabilizer is sorbitol supplemented into the medium at a concentration between 0.1 M and 1.5 M, preferably at 0.5 M or 1.0 M. Cultured mammalian cells are generally cultured in commercially available serum- containing or serum-free media. Selection of a medium and growth conditions appropriate for the particular cell line used is within the level of ordinary skill in the art.
D -1 Type 3 receptors may also be expressed in non-human transgenic animals, particularly transgenic warm-blooded animals. Methods for producing transgenic animals, including mice, rats, rabbits, sheep and pigs, are known in the art and are disclosed, for example, by Hammer et al. (Nature 375:680-683, 1985), Palmiter et al. (Science 222:809-814, 1983), Brinster et al. (Proc. Natl. Acad Sci. USA 52:4438- 4442, 1985), Palmiter and Brinster (Cell */:343-345, 1985) and U.S. Patent No. 4,736,866, which are incoφorated herein by reference. Briefly, an expression unit, including a DNA sequence to be expressed together with appropriately positioned expression control sequences, is introduced into pronuclei of fertilized eggs. Introduction of DNA is commonly done by microinjection. Integration of the injected DNA is detected by blot analysis of DNA from tissue samples, typically samples of tail tissue. It is generally preferred that the introduced DNA be incoφorated into the germ line of the animal so that it is passed on to the animal's progeny.
Within particularly preferred embodiments of the invention, "knockout" animals may be developed from embryonic stem cells through the use of homologous recombination (Capecchi, Science 244: 1288-1292, 1989) or antisense oligonucleotide (Stein and Chen, Science 267(5124): 1004- 1012, 1993; Milligan et al., Semin. Cone. Biol. 3(6):391-398, 1992).
Within a preferred embodiment of the invention, a transgenic animal, such as a mouse, is developed by targeting a mutation to disrupt a IL-l Type 3 receptor sequence (see Mansour et al., "Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: A general strategy for targeting mutations to non-selectable genes," Nature 336:348-352, 1988). Such animals may readily be utilized as a model to study the role of the IL-l Type 3 receptor in metabolism.
SOLUBLE IL-l TYPE 3 RECEPTORS AND RECEPTOR PEFΠDES As noted above, the present invention also provides soluble IL-l Type 3 receptors and receptor peptides. Within the context of the present invention, IL-l Type 3 receptor peptides should be understood to include portions of a IL-l Type 3 receptor or derivatives thereof discussed above, which do not contain transmembrane domains, and which are at least 8, and more preferably 10 or greater amino acids in length. Briefly, the structure of the IL-l Type 3 receptor as well as putative transmembrane domains may be predicted from the primary translation products using the hydrophopicity plot function of, for example, PROTEAN (DNA STAR, Madison, WI), or according to the methods described by Kyte and Doolittle (J. Mol. Biol. 757:105- 132, 1982). While not wishing to be bound by a graphical representation, based upon this hydrophopicity analysis, IL-l Type 3 receptors are believed to have the general structure shown in Figure 1. In particular, these receptors are believed to comprise an extracellular amino-terminal domain, a transmembrane domain, and an intracellular domain.
Within one aspect of the invention, isolated IL-l Type 3 receptor peptides are provided comprising the extracellular amino-terminal domain of a IL-l Type 3 receptor. Within a preferred embodiment, an isolated IL-l Type 3 receptor peptide is provided comprising the sequence of amino acids shown in Sequence I.D. No.2, from amino acid number 1 to amino acid number 336. Within other embodiments, isolated IL-l Type 3 receptor peptides are provided comprising the sequence of amino acids shown in Sequence I.D. No. 4, from amino acid number 1 to amino acid number 338.
IL-l Type 3 receptor peptides may be prepared by, among other methods, culturing suitable host vector systems to produce the recombinant translation products of the present invention. Supernatants from such cell lines may then be treated by a variety of purification procedures in order to isolate the IL-l Type 3 receptor peptide. For example, the supernatant may be first concentrated using commercially available protein concentration filters, such as an Amicon or Millipore Pellicon ultrafiltration unit. Following concentration, the concentrate may be applied to a suitable purification matrix such as, for example, IL-l or an anti-IL-1 Type 3 receptor antibody bound to a suitable support. Alternatively, anion or cation exchange resins may be employed in order to purify the receptor or peptide. Finally, one or more reversed-phase high performance liquid chromatography (RP-HPLC) steps may be employed to further purify the IL-l Type 3 receptor peptide.
Alternatively, IL-l Type 3 receptor peptides may also be prepared utilizing standard polypeptide synthesis protocols, and purified utilizing the above- described procedures.
A IL-l Type 3 receptor peptide is deemed to be "isolated" or purified within the context of the present invention, if only a single band is detected subsequent to SDS-polyacrylamide gel analysis followed by staining with Coomassie Brilliant Blue.
ANTIBODIES TO IL-l TYPE 3 RECEPTORS Within one aspect of the present invention, IL-l Type 3 receptors, including derivatives thereof, as well as portions or fragments of these proteins such as the IL-l Type 3 receptor peptides discussed above, may be utilized to prepare antibodies which specifically bind to IL-l Type 3 receptors. Within the context of the present invention the term "antibodies" includes polyclonal antibodies, monoclonal antibodies, fragments thereof such as F(ab')2 and Fab fragments, as well as recombinantly produced binding partners. These binding partners incoφorate the variable regions from a gene which encodes a specifically binding monoclonal antibody. Antibodies are defined to be specifically binding if they bind to the IL-l Type 3 receptor with a KA of greater than or equal to IO7 M"1 and preferably greater than or equal to 108M_1, and bind to IL-l Type I or Type II receptors with an affinity of less than KA IO7 M"1, and preferably less than 105M_1 or 103M"1. The affinity of a monoclonal antibody or binding partner may be readily determined by one of ordinary skill in the art (see Scatchard, Ann. NY. Acad. Sci. 57:660-672, 1949).
Polyclonal antibodies may be readily generated by one of ordinary skill in the art from a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, or rats. Briefly, the IL-l Type 3 receptor is utilized to immunize the animal through intraperitoneal, intramuscular, intraocular, or subcutaneous injections. The immunogenicity of a IL-l Type 3 receptor or IL-l Type 3 receptor peptide may be increased through the use of an adjuvant such as Freund's complete or incomplete adjuvant. Following several booster immunizations, small samples of serum are collected and tested for reactivity to the IL-l Type 3 receptor. A variety of assays may be utilized in order to detect antibodies which specifically bind to a IL-l Type 3 receptor. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane (eds ), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: Countercurrent Immuno-Electrophoresis (CIEP), Radioimmunoassays, Radioimmunoprecipitations, Enzyme-Linked Immuno-Sorbent Assays (ELISA), Dot Blot assays, Inhibition or Competition assays, and sandwich assays (see U.S. Patent Nos. 4,376, 1 10 and 4,486,530; see also Antibodies: A Laboratory Manual, supra). Particularly preferred polyclonal antisera will give a signal that is at least three times greater than background. Once the titer of the animal has reached a plateau in terms of its reactivity to the IL-l Type 3 receptor, larger quantities of polyclonal antisera may be readily obtained either by weekly bleedings, or by exsanguinating the animal.
Monoclonal antibodies may also be readily generated using well-known techniques (see U.S. Patent Nos. RE 32,01 1, 4,902,614, 4,543,439, and 4,41 1,993; see also Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Plenum Press, Kennett, McKearn, and Bechtol (eds ), 1980, and Antibodies: A Laboratory Manual, Harlow and Lane (eds ), Cold Spring Harbor Laboratory Press, 1988). Briefly, within one embodiment a subject animal such as a rat or mouse is injected with a form of IL-l Type 3 receptor suitable for generating an immune response against the IL-l Type 3 receptor. Representative examples of suitable forms include, among others, cells which express the IL-l Type 3 receptor, or peptides which are based upon the IL-l Type 3 receptor sequence. Additionally, many techniques are known in the art for increasing the resultant immune response, for example, by coupling the receptor or receptor peptides to another protein such as ovalbumin or keyhole limpet hemocyanin (KLH), or through the use of adjuvants such as Freund's complete or incomplete adjuvant. The initial immunization may be through intraperitoneal, intramuscular, intraocular, or subcutaneous routes.
Between one and three weeks after the initial immunization the animal may be reimmunized with another booster immunization. The animal may then be test bled and the serum tested for binding to the IL-l Type 3 receptor using assays as described above. Additional immunizations may also be accomplished until the animal has plateaued in its reactivity to the IL-l Type 3 receptor. The animal may then be given a final boost of IL-l Type 3 receptor or IL-l Type 3 receptor peptide, and three to four days later sacrificed. At this time, the spleen and lymph nodes may be harvested and disrupted into a single cell suspension by passing the organs through a mesh screen or by rupturing the spleen or lymph node membranes which encapsidate the cells. Within one embodiment the red cells are subsequently lysed by the addition of a hypotonic solution, followed by immediate return to isotonicity.
Within another embodiment, suitable cells for preparing monoclonal antibodies are obtained through the use of in vitro immunization techniques. Briefly, an animal is sacrificed, and the spleen and lymph node cells are removed as described above. A single cell suspension is prepared, and the cells are placed into a culture containing a form of the IL-l Type 3 receptor that is suitable for generating an immune response as described above. Subsequently, the lymphocytes are harvested and fused as described below. Cells which are obtained through the use of in vitro immunization or from an immunized animal as described above may be immortalized by transfection with a virus such as the Epstein-Barr virus (EBV) (see Glasky and Reading, Hybridoma 5(4):377-389, 1989). Alternatively, within a preferred embodiment, the harvested spleen and/or lymph node cell suspensions are fused with a suitable myeloma cell in order to create a "hybridoma" which secretes monoclonal antibodies. Suitable myeloma lines are preferably defective in the construction or expression of antibodies, and are additionally syngeneic with the cells from the immunized animal. Many such myeloma cell lines are well known in the art and may be obtained from sources such as the American Type Culture Collection (ATCC), Rockville, Maryland (see Catalogue of Cell Lines & Hybridomas, 6th ed., ATCC, 1 88). Representative myeloma lines include: for humans, UC 729-6 (ATCC No. CRL 8061), MC/CAR-Z2 (ATCC No. CRL 8147), and SKO-007 (ATCC No. CRL 8033); for mice, SP2/0-Agl4 (ATCC No. CRL 1581), and P3X63Ag8 (ATCC No. TIB 9); and for rats, Y3-Agl .2.3 (ATCC No. CRL 1631), and YB2/0 (ATCC No. CRL 1662). Particularly preferred fusion lines include NS-1 (ATCC No. TIB 18) and P3X63 - Ag 8.653 (ATCC No. CRL 1580), which may be utilized for fusions with either mouse, rat, or human cell lines. Fusion between the myeloma cell line and the cells from the immunized animal may be accomplished by a variety of methods, including the use of polyethylene glycol (PEG) (see Antibodies: A Laboratory Manual, Harlow and Lane (eds ), Cold Spring Harbor Laboratory Press, 1988) or electrofusion (see Zimmerman and Vienken, J. Membrane Biol. 67: 165-182, 1982).
Following the fusion, the cells are placed into culture plates containing a suitable medium, such as RPMI 1640 or DMEM (Dulbecco's Modified Eagles Medium) (JRH Biosciences, Lenexa, KS). The medium may also contain additional ingredients, such as Fetal Bovine Serum ("FBS," i.e., from Hyclone, Logan, Utah, or JRH Biosciences), thymocytes which were harvested from a baby animal of the same species as was used for immunization, or agar to solidify the medium. Additionally, the medium should contain a reagent which selectively allows for the growth of fused spleen and myeloma cells. Particularly preferred is the use of HAT (hypoxanthine, aminopterin, and thymidine) (Sigma Chemical Co., St. Louis, MO). After about seven days, the resulting fused cells or hybridomas may be screened in order to determine the presence of antibodies which recognize the IL-l Type 3 receptor. Following several clonal dilutions and reassays, a hybridoma producing antibodies which bind to IL-l Type 3 receptor may be isolated.
Other techniques may also be utilized to construct monoclonal antibodies (see Huse et al., "Generation of a Large Combinational Library of the Immunoglobulin Repertoire in Phage Lambda," Science 2*6: 1275-1281, December 1989; see also Sastry et al., "Cloning of the Immunological Repertoire in Escherichia coli for Generation of Monoclonal Catalytic Antibodies: Construction of a Heavy Chain Variable Region- Specific cDNA Library," Proc. Natl. Acad. Sci. USA 56:5728-5732, August 1989; see also Alting-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas," Strategies in Molecular Biology 3:1-9, January 1990; these references describe a commercial system available from Stratacyte, La Jolla, California, which enables the production of antibodies through recombinant techniques). Briefly, mRNA is isolated from a B cell population and utilized to create heavy and light chain immunoglobulin cDNA expression libraries in the kIMMUNOZAP(H) and kIMMUNOZAP(L) vectors. These vectors may be screened individually or co- expressed to form Fab fragments or antibodies (see Huse et al., supra, see also Sastry et al., supra). Positive plaques may subsequently be converted to a non-lytic plasmid which allows high level expression of monoclonal antibody fragments from E. coli.
Similarly, binding partners may also be constructed utilizing recombinant DNA techniques to incoφorate the variable regions of a gene which encodes a specifically binding antibody. The construction of these proteins may be readily accomplished by one of ordinary skill in the art (see Larrick et al., "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells," Biotechnology 7:934-938, September 1989; Riechmann et al., "Reshaping Human Antibodies for Therapy," Nature 332:323- 327, 1988; Roberts et al., "Generation of an Antibody with Enhanced Affinity and Specificity for its Antigen by Protein Engineering," Nature 325:731-734, 1987; Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," Science 239:1534-1536, 1988; Chaudhary et al., "A Recombinant Immunotoxin Consisting of Two Antibody Variable Domains Fused to Pseudomonas Exotoxin," Nature 339:394-397, 1989; see also, U.S. Patent No. 5,132,405 entitled "Biosynthetic Antibody Binding Sites"), given the disclosure provided herein. Briefly, within one embodiment, DNA molecules encoding IL-l Type 3 receptor-specific antigen binding domains are amplified from hybridomas which produce a specifically binding monoclonal antibody, and inserted directly into the genome of a cell which produces human antibodies (see Verhoeyen et al., supra, see also Reichmann et al., supra). This technique allows the antigen-binding site of a specifically binding mouse or rat monoclonal antibody to be transferred into a human antibody. Such antibodies are preferable for therapeutic use in humans because they are not as antigenic as rat or mouse antibodies.
Alternatively, the antigen-binding sites (variable region) may be either linked to, or inserted into, another completely different protein (see Chaudhary et al., supra), resulting in a new protein with antigen-binding sites of the antibody as well as the functional activity of the completely different protein. As one of ordinary skill in the art will recognize, the antigen-binding sites or IL-l Type 3 receptor binding domain of the antibody may be found in the variable region of the antibody. Furthermore, DNA sequences which encode smaller portions of the antibody or variable regions which specifically bind to mammalian IL-l Type 3 receptor may also be utilized within the context of the present invention. These portions may be readily tested for binding specificity to the IL-l Type 3 receptor utilizing assays described below.
Within a preferred embodiment, genes which encode the variable region from a hybridoma producing a monoclonal antibody of interest are amplified using oligonucleotide primers for the variable region. These primers may be synthesized by one of ordinary skill in the art, or may be purchased from commercially available sources. Stratacyte (La Jolla, CA) sells primers for mouse and human variable regions including, among others, primers for VHa, VHb, VHc, VHd, CHl, VL and CL regions. These primers may be utilized to amplify heavy or light chain variable regions, which may then be inserted into vectors such as IMMUNOZAP*(H) or IMMUNOZAP*(L) (Stratacyte), respectively. These vectors may then be introduced into E. coli for expression. Utilizing these techniques, large amounts of a single-chain protein containing a fusion of the VH and VL domains may be produced (see Bird et al., Science 242:423-426, 1988). Other "antibodies" which may also be prepared utilizing the disclosure provided herein, and thus which are also deemed to fall within the scope of the present invention include humanized antibodies (e.g., U.S. Patent No. 4,816,567 and WO 94/10332), micobodies (e.g., WO 94/09817) and transgenic antibodies (e.g., GB 2 272 440). Once suitable antibodies have been obtained, they may be isolated or purified by many techniques well known to those of ordinary skill in the art (see Antibodies: A Laboratory Manual, supra). Suitable techniques include peptide or protein affinity columns, HPLC or RP-HPLC, purification on protein A or protein G columns, or any combination of these techniques. Within the context of the present invention, the term "isolated" as used to define antibodies or binding partners means "substantially free of other blood components." Antibodies of the present invention have many uses. For example, antibodies may be utilized in flow cytometry to sort IL-l Type 3 receptor-bearing cells, or to histochemically stain IL-l Type 3 receptor-bearing tissues. Briefly, in order to detect IL-l Type 3 receptors on cells, the cells (or tissue) are incubated with a labeled antibody which specifically binds to IL-l Type 3 receptors, followed by detection of the presence of bound antibody. These steps may also be accomplished with additional steps such as washings to remove unbound antibody. Representative examples of suitable labels, as well as methods for conjugating or coupling antibodies to such labels are described in more detail below.
In addition, purified antibodies may also be utilized therapeutically to block the binding of IL-l or other IL-l Type 3 receptor substrates to the IL-l Type 3 receptor in vitro or in vivo. As noted above, a variety of assays may be utilized to detect antibodies which block or inhibit the binding of IL-l to the IL-l Type 3 receptor, including inter alia, inhibition and competition assays noted above. Within one embodiment, monoclonal antibodies (prepared as described above) are assayed for binding to the IL-l Type 3 receptor in the absence of IL-l, as well as in the presence of varying concentrations of IL-l. Blocking antibodies are identified as those which, for example, bind to IL-l Type 3 receptors and, in the presence of IL-l, block or inhibit the binding of IL-l to the IL-l Type 3 receptor.
Antibodies of the present invention may also be coupled or conjugated to a variety of other compounds (or labels) for either diagnostic or therapeutic use. Such compounds include, for example, toxic molecules, molecules which are nontoxic but which become toxic upon exposure to a second compound, and radionuclides. Representative examples of such molecules are described in more detail below.
Antibodies which are to be utilized therapeutically are preferably provided in a therapeutic composition comprising the antibody or binding partner and a physiologically acceptable carrier or diluent. Suitable carriers or diluents include, among others, neutral buffered saline or saline, and may also include additional excipients or stabilizers such as buffers, sugars such as glucose, sucrose, or dextrose, chelating agents such as EDTA, and various preservatives. LABELS The nucleic acid molecules, antibodies, and IL-l Type 3 receptors (including sIL-1 3R) of the present invention may be labeled or conjugated (either through covalent or non-covalent means) to a variety of labels or other molecules, including for example, fluorescent markers, enzyme markers, toxic molecules, molecules which are nontoxic but which become toxic upon exposure to a second compound, and radionuclides.
Representative examples of fluorescent labels suitable for use within the present invention include, for example, Fluorescein Isothiocyanate (FITC), Rhodamine, Texas Red, Luciferase and Phycoerythrin (PE). Particularly preferred for use in flow cytometry is FITC which may be conjugated to purified antibody according to the method of Keltkamp in "Conjugation of Fluorescein Isothiocyanate to Antibodies. I. Experiments on the Conditions of Conjugation," Immunology 75:865-873, 1970. (See also Keltkamp, "Conjugation of Fluorescein Isothiocyanate to Antibodies. II. A Reproducible Method," Immunology 75:875-881, 1970; and Goding, "Conjugation of Antibodies with Fluorochromes: Modification to the Standard Methods," J. Immunol. Methods 73:215-226, 1970.) For histochemical staining, HRP, which is preferred, may be conjugated to the purified antibody according to the method of Nakane and Kawaoi ("Peroxidase-Labeled Antibody: A New Method of Conjugation," J. Histochem. Cytochem. 22: 1084-1091, 1974; see also, Tijssen and Kurstak, "Highly Efficient and Simple Methods for Preparation of Peroxidase and Active Peroxidase Antibody Conjugates for Enzyme Immunoassays," Anal. Biochem. 736:451-457, 1984).
Representative examples of enzyme markers or labels include alkaline phosphatase, horse radish peroxidase, and β-galactosidase. Representative examples of toxic molecules include ricin, abrin, diphtheria toxin, cholera toxin, gelonin, pokeweed antiviral protein, tritin, Shigella toxin, and Pseudomonas exotoxin A. Representative examples of molecules which are nontoxic, but which become toxic upon exposure to a second compound include thymidine kinases such as HSVTK and VZVTK. Representative examples of radionuclides include Cu-64, Ga-67, Ga-68, Zr-89, Ru-97, Tc-99m, Rh-105, Pd-109, In-I l l, 1-123, 1-125, 1-131, Re-186, Re-188, Au-198, Au- 199, Pb-203, At-211, Pb-212 and Bi-212.
As will be evident to one of skill in the art given the disclosure provided herein, the above described nucleic acid molecules, antibodies, and IL-l Type 3 receptors may also be labeled with other molecules such as colloidal gold, as well either member of a high affinity binding pair (e.g., avidin-biotin). DIAGNOSTIC USE OF IL-l TYPE 3 RECEPTOR SEQUENCES Within another aspect of the present invention, probes and primers are provided for detecting IL-l Type 3 receptors. Within one embodiment of the invention, probes are provided which are capable of hybridizing to IL-l Type 3 receptor DNA or RNA. For puφoses of the present invention, probes are "capable of hybridizing" to IL- 1 Type 3 receptor DNA if they hybridize to Sequence I.D. Nos. 1 or 3 under conditions of moderate or high stringency (see Sambrook et al., supra); but not to IL-l Type I or Type π receptor nucleic acid sequences. Preferably, the probe may be utilized to hybridize to suitable nucleotide sequences in the presence of 50% formamide, 5x SSPE, 5x Denhardt's, 0.1% SDS and 100 ug/ml Salmon Sperm DNA at 42°C, followed by a first wash with 2x SSC at 42°C, and a second wash with 0.2x SSC at 55 to 60°C.
Probes of the present invention may be composed of either deoxyribonucleic acids (DNA) ribonucleic acids (RNA), nucleic acid analogues, or any combination of these, and may be as few as about 12 nucleotides in length, usually about 14 to 18 nucleotides in length, and possibly as large as the entire sequence of the IL-l Type 3 receptor. Selection of probe size is somewhat dependent upon the use of the probe. For example, in order to determine the presence of various polymoφhic forms of the IL-l Type 3 receptor within an individual, a probe comprising virtually the entire length of the IL-l Type 3 receptor coding sequence is preferred. IL-l Type 3 receptor probes may be utilized to identify polymoφhisms linked to the IL-l Type 3 receptor gene (see, for example, Weber, Genomics 7:524-530, 1990; and Weber and May, Amer. J. Hum. Gen. 4*388-396, 1989). Such polymoφhisms may be associated with inherited diseases such as diabetes.
Probes may be constructed and labeled using techniques which are well known in the art. Shorter probes of, for example, 12 or 14 bases may be generated synthetically. Longer probes of about 75 bases to less than 1.5 kb are preferably generated by, for example, PCR amplification in the presence of labeled precursors such as 32P-dCTP, digoxigenin-dUTP, or biotin-dATP. Probes of more than 1.5 kb are generally most easily amplified by transfecting a cell with a plasmid containing the relevant probe, growing the transfected cell into large quantities, and purifying the relevant sequence from the transfected cells (see Sambrook et al., supra).
Probes may be labeled by a variety of markers, including, for example, radioactive markers, fluorescent markers, enzymatic markers, and chromogenic markers. The use of 32P is particularly preferred for marking or labeling a particular probe. Probes of the present invention may also be utilized to detect the presence of a IL-l Type 3 receptor mRNA or DNA within a sample. However, if IL-l Type 3 receptors are present in only a limited number, or if it is desired to detect a selected mutant sequence which is present in only a limited number, or if it is desired to clone a IL-l Type 3 receptor from a selected warm-blooded animal, then it may be beneficial to amplify the relevant sequence such that it may be more readily detected or obtained. A variety of methods may be utilized in order to amplify a selected sequence, including, for example, RNA amplification (see Lizardi et al., Bio/Technology 6:1197-1202, 1988; Kramer et al., Nature 339:401-402, 1989; Lomeli et al., Clinical Chem. 35(9): 1826-1831, 1989; U.S. Patent No. 4,786,600), and DNA amplification utilizing Polymerase Chain Reaction ("PCR") (see U.S. Patent Nos. 4,683,195, 4,683,202, and 4,800, 159) (see also, U.S. Patent Nos. 4,876,187, and 5,011,769, which describe an alternative detection amplification system comprising the use of scissile linkages).
Within a particularly preferred embodiment, PCR amplification is utilized to detect or obtain a IL-l Type 3 receptor DNA. Briefly, as described in greater detail below, a DNA sample is denatured at 95°C in order to generate single stranded DNA. Specific primers, as discussed below, are then annealed at 37°C to 70°C, depending on the proportion of AT/GC in the primers. The primers are extended at 72°C with Taq polymerase in order to generate the opposite strand to the template. These steps constitute one cycle, which may be repeated in order to amplify the selected sequence. Primers for the amplification of a selected sequence should be selected from sequences which are highly specific and form stable duplexes with the target sequence. The primers should also be non-complementary, especially at the 3' end, should not form dimers with themselves or other primers, and should not form secondary structures or duplexes with other regions of DNA. In general, primers of about 18 to 20 nucleotides are preferred, and may be easily synthesized using techniques well known in the art.
PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USES
As noted above, the present invention provides pharmaceutical compositions, as well as methods for using the same (for either prophylactic or therapeutic use). Briefly, the pharmaceutical compositions of the present invention may comprise an IL-l 3R, sIL-1 3R, antibody which is capable of specifically binding IL- 1 3R, IL-l 3R antagonists or agonists, in combination with a pharmaceutically acceptable carrier, diluent, or excipient. Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like, carbohydrates such as glucose, mannose, sucrose or dextrose, proteins, polypeptides or amino acids, antioxidants, chelating agents such as EDTA or glutathione, and preservatives. Compositions of the present invention may be formulated for the manner of administration indicated, including for example, for oral, nasal, venous, vaginal or rectal administration. Within other embodiments, the compositions may be administered as part of a sustained release implant (e.g., intra-articularly). Within yet other embodiments, the compositions may be formulized as a lyophilizate, utilizing appropriate excipients which provide stability as a lyophilizate, and subsequent to rehydration.
Pharmaceutical compositions of the present invention may be utilized in order to treat a wide variety of diseases including, for example, immune-associated diseases such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, myasthemia gravis, scleritis, scleroderma, septic shock, allograft rejection, and graft versus host (GVH) disease. In particular, pharmaceutical compositions of the present invention may be administered in a manner appropriate to the disease to be treated (or prevented). Although appropriate dosages may be determined by clinical trials, the quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patient's disease.
Within other aspects of the present invention, viral vectors are provided which may be utilized to treat diseases wherein either the IL-l Type 3 receptor (or a mutant IL-l Type 3 receptor) is over-expressed, or where no IL-l Type 3 receptor is expressed. Briefly, within one embodiment of the invention, viral vectors are provided which direct the production of antisense IL-l Type 3 receptor RNA, in order to prohibit the over-expression of IL-l Type 3 receptors, or the expression of mutant IL-l Type 3 receptors. Within another embodiment, viral vectors are provided which direct the expression of IL-l Type 3 receptor cDNA. Viral vectors suitable for use in the present invention include, among others, recombinant vaccinia vectors (U.S. Patent Nos. 4,603,112 and 4,769,330), recombinant pox virus vectors (PCT Publication No. WO 89/01973), and preferably, recombinant retroviral vectors ("Recombinant Retroviruses with Amphotropic and Ecoptropic Host Ranges," PCT Publication No. WO 90/02806; "Retroviral Packaging Cell Lines and Processes of Using Same," PCT Publication No. WO 89/07150; and "Antisense RNA for Treatment of Retroviral Disease States," PCT Publication No. WO/03451), and heφesvirus vectors (Kit, Adv. Exp. Med Biol. 275:219-236, 1989; U.S. Patent No. 5,288,641).
Within various embodiments of the invention, the above-described compositions may be administered in vivo, or ex vivo. Representative routes for in vivo administration include intradermally ("i.d."), intracranially ("i.e."), intraperitoneally ("i.p."), intrathecally ("i.t."), intravenously ("i.v "), subcutaneously ("s.c") or intramuscularly ("i.m "). Within other embodiments of the invention, the vectors which contain or express nucleic acid molecules of the present invention, or even the nucleic acid molecules themselves, may be administered by a variety of alternative techniques, including for example direct DNA injection (Acsadi et al., Nature 352:815-818, 1991); microprojectile bombardment (Williams et al., PNAS 55:2726-2730, 1991); liposomes (Pickering et al., Circ. 59(1):13-21, 1994; and Wang et al., PNAS 5*7851-7855, 1987); lipofection (Feigner et al., Proc. Natl. Acad. Sci. USA 5*7413-7417, 1989); DNA ligand (Wu et al., J. of Biol. Chem. 26* 16985-16987, 1989); administration of DNA linked to killed adenovirus (Michael et al., J. Biol. Chem. 265(10):6866-6869, 1993; and Curiel et al., Hum. Gene Ther. 3(2): 147-154, 1992), retrotransposons, cytofectin- mediated introduction (DMRBE-DOPE, Vical, Calif.) and transferrin-DNA complexes (Zenke).
The following examples are offered by way of illustration, and not by way of limitation.
EXAMPLES
EXAMPLE 1 ISOLATION OF INTERLEUKIN- 1 TYPE 3 RECEPTOR cDN A
A. Isolation of Interleukin- 1 Type 3 Receptor cDNA From a Rat Lung cDNA Library
Male Sprague-Dawley rats (Madison, WI) weighing between 175-250 gm are decapitated, and the lungs excised. Total RNA is then isolated from the lung utilizing a Promega RNAgents Total RNA Kit (catalog #Z51 10, Promega, Wise.) according to the manufacturers instructions, followed by the isolation of poly A+ RNA utilizing a Promega PolyATract kit (catalog # Z5420). A cDNA phage library is then prepared utilizing a Giga-Pack Gold library construction kit according to the manufacturers' instructions (catalog #23761 1, Stratagene, LaJolla, Calif), which is in turn plated and screened essentially as described by Sambrook et al., (Molecular Cloning) with oligonucleotide (5'-CTTCAACTGC ACATACCCTC CAGTAACAAA CGGGGCAGTG AATCTGACAT-3') (Sequence I.D. No. 6). This oligonucleotide is complementary to nucleotides 211-260 of the rat IL-l Type 3 receptor cDNA sequence shown in Sequence I.D. No. 3.
The phage library is rescreened until a single pure phage isolate is obtained. The phage is then grown on bacterial host XL 1 -Blue (Stratagene, LaJolla, Calif), and plasmid DNA is excised with ExAssist helper phage (Stratagene) in SOLR cells. The SOLR cells are then plated, and plasmid DNA is isolated and sequenced utilizing the Sanger dideoxy protocol.
A rat IL-l Type 3 receptor cDNA sequence that may be obtained utilizing this procedure is set forth in Sequence I.D. No. 3.
B. Isolation of Interleukin- 1 Type 3 Receptor cDNA From a Commericallv Available Rat cDNA Library
IL-l Type 3 receptor cDNA can also be isolated from commercially available rat cDNA libraries. For example, two million plaques from a rat phage library
(Clontech, catalog # RL 1048a) may be plated according to the manufacturer's instructions, and screened with oligonucleotide Sequence I.D. No. 6 essentially as described above.
A rat IL-l Type 3 receptor cDNA sequence that may be obtained utilizing this procedure is set forth in Sequence I.D. No.3. C. Isolation of IL-l Type 3 Receptor cDNA From a Human cDNA Library
IL-l Type 3 receptor cDNA can also be isolated from commercially available human cDNA libraries. Briefly, approximately two million plaques from a human phage library (Clontech, catalog # HL1 158a) are plated according to the manufacturers instructions, and screened with oligonucleotide (5'-CCTCCCATAA
CATCTGGGGA AGTCAGTGTA ACATGGTATA AAAATTCTAG C-3') (Sequence
I.D. No. 7) essentially as described above. This oligonucleotide is complementary to nucleotides 260-310 of the human IL-l Type 3 receptor cDNA sequence shown in Sequence I.D. No. 1.
The phage library is rescreened and isolated as described above. The human sequence that is obtained utilizing this procedure is approximately 89.1% identical at the nucleotide level and 89.2% identical at the amino acid level to that of the common region of the above-described rat IL-l Type 3 receptors.
EXAMPLE 2 EXPRESSION OF IL-l TYPE 3 RECEPTOR CDNA
A. Expression of Rat Interleukin- 1 Type 3 Receptor
In order to express IL-l Type 3 receptor cDNA, a mammalian cell expression vector (pCDM7amp) is first constructed. Briefly, pCDM7amp is a DNA plasmid which contains 1) an ampicillin resistance gene that provides for selection in prokaryotic cells, 2) a bacterial origin of replication which allows propagation and amplification in host bacterial cells, 3) a CMV (cytomegalovirus) promoter which sponsors transcription in mammalian cells, 4) a multiple cloning site (MCS), which is a series of adjacent restriction sites in the DNA sequence that are useful for the insertion of appropriate DNA fragments, and 5) a SV 40 T-antigen splice and polyadenylation site. pCDM7-Amp is constructed from pCDM8 (Seed, Nature 329:840-842,
1987; Seed and Aruffb, Proc. Natl. Acad. Sci. 84:3365-3369, 1987; Thomsen et al., Cell 63:485-493, 1990; Bernot and Auffray, Proc. Natl. Acad. Sci 88:2550-2554, 1991; Han et al., Nature 349:697-700, 1991) by deletion of the adeno origin of replication, M13 origin of replication and sup F selection marker. An ampicillin resistance marker is then added in order to facilitate selection of the plasmid.
A full-length rat IL-l Type 3 receptor clone in pBluescriptSK- is isolated from the phage clone described above, and cut with EcoRV and Hindlll, releasing two inserts. The inserts are then isolated and ligated to pCDM7-Amp which had been similarly cut. The resulting product is used to transform E. coli DH5α, and colonies are examined by restriction digests for correct orientation of the two inserts (i.e., proper formation of the IL-l Type 3R coding sequence.) COS-7 (ATCC No. CRL 1651) cells are then transfected with pCDM7-
Amp containing IL-l Type 3 receptor cDNA (10 ug DNA/ 10 cm plate of cells) utilizing 400 μg/ml of DEAE-Dextran and 100 μM chloroquine. The cells are transfected for 4 hours, then shocked with 10% DMSO for 2 minutes. The cells are then washed, and grown in DMEM containing 10% Fetal Bovine Serum for 2 days in a 24-well plate.
B. Expression of Human Interleukin- 1 Type 3 Receptor A full-length human IL-l Type 3 receptor clone in pBluescriptSK- is isolated from the phage clone described above, and cut with Not! and ΛTrøl, releasing the insert. The insert is then isolated and ligated to pCDM7-Amp which had been similarly cut. The resulting product is used to transform E. coli DH5α, from which larger quantities of plasmid DNA may be isolated.
COS-7 (ATCC No. CRL 1651) cells are then transfected with pCDM7- A p containing IL-l Type 3 receptor cDNA (10 ug DNA 10 cm plate of cells) utilizing 400 μg/ml of DEAE-Dextran and 100 μM chloroquine. The cells are transfected for 4 hours, then shocked with 10% DMSO for 2 minutes. The cells are then washed, and grown in DMEM containing 10% Fetal Bovine Serum for 2 days in a 24-well plate.
EXAMPLE 3 CONSTRUCTION AND EXPRESSION OF SOLUBLE
HUMAN INTERLEUKIN- l TYPE 3 RECEPTOR
A. Plasmid Construction
1. Vector Preparation An expression vector containing the N-terminal portion of the human BL-
1 type 3 receptor, also referred to as the "soluble" form of the receptor, is constructed essentially as described below. Briefly, pCDM7amp DNA (as described above) is subjected to restriction endonuclease digestion with two enzymes, Notl and Xhol, each of which have one recognition site in this vector, both located in the MCS. The product is a linearized DNA fragment with the CMV promoter/enhancer immediately upstream of the cut site, and the polyadenylation signal downstream of the cut site. After digestion, the cleaved vector is isolated by agarose gel electrophoresis and purified using the Gene Clean procedure (Bio 101, San Diego, CA). The vector is now ready to combine with a DNA fragment encoding the soluble human IL-l type 3 receptors.
2. Insert Preparation Into this prepared vector is ligated a DNA fragment containing the coding region of the first 336 amino acids of the human IL-l type 3 receptor set forth in Sequence ID No. 1 (from nucleotide number 129 to nucleotide number 1 136). Briefly, two oligonucleotides are first synthesized for use as primers in
PCR. These oligonucleotides can be synthesized on a DNA synthesizer. The first primer consists of the sequence 5'-CCTACTCGAG ATGTGGTCCT TGCTGCTC-3' (Sequence ID No: 8). The first four nucleotides of this sequence serve as a spacer, and increase the efficiency of endonuclease cleavage in a subsequent reaction to be described. Nucleotides 5 through 10 encode a Xhol endonuclease cleavage site, and nucleotides 1 1 through 28 are identical to the N-terminal coding region of the human IL-type 3 receptor (nucleotides 129 to 146 in Sequence ID No: 1)).
The second primer consists of the sequence 5'-ATGCGCGGCC GCCTATCGAA AATCCGGAGC TGG-3' (Sequence Id No: 9). The first four nucleotides of this sequence serve as a spacer, and increase efficiency of endonuclease cleavage in a subsequent reaction to be described. Nucleotides 5 through 12 encode a No/I endonuclease cleavage site. Nucleotides 13 through 15 encode a translation stop codon, and nucleotides 16 though 33 are complementary to the coding region of the human IL-l type 3 receptor immediately preceding the transmembrane region (nucleotides 1133 through 11 16 in Sequence ID No. 1).
The fragment encoding soluble human IL-l type 3 receptor is then generated by PCR. Briefly, lOOng of each primer are combined in a 0.5ml test tube, along with lng of the entire human IL-l type 3 receptor DNA sequence contained in a cloning vector, such as Bluescript (Stratagene, La Jolla, CA). Ten microliters of 10X PCR buffer, 5ul of 25mM MgCl, lul of 25mM aTP, and lul of Taq polymerase/Vent polymerase (16: 1 ratio) are also added to the reaction. The complete sample is then overlayed with lOOul of mineral oil to prevent evaporation, and the sample is placed in a thermocycler. Reaction conditions are: 94°C for 15 seconds, 55°C for 60 seconds, and 72°C for 60 seconds. These conditions are repeated for 25 cycles. Product from the reaction is analyzed by agarose gel electrophoresis to verify the size of the fragment (1009 bp) and also to determine the approximate amount of DNA generated. The DNA is then isolated by phenol/chloroform extraction and purified over a G-50 mini-spin column (Boehringer Mannheim, Indianapolis, IN) Approximately lOug of the purified DNA fragment is digested with 20 units each of Xhol and NotI restriction endonucleases in a standard reaction to generate cohesive ends on the fragment which are compatible with the pCDM7 vector prepared as detailed above. The digested fragment is then agarose gel purified to remove impurities and contaminating DNA species.
3. Ligation
One hundred nanograms of vector DNA is combined with lOOng of insert DNA in a 1.5ml mini-tube with lul of 10X ligation buffer, lul of DNA ligase (Boehringer Mannheim), and water to a total volume of lOul. This sample is incubated at 23°C for 2 hours.
4. Transformation One hundred microliters of competent E. coli bacteria cells are combined with the ligation product and incubated on ice for 30 minutes. The sample is then incubated at 42°C for 45 seconds. One milliliter of bacterial medium (Circle Grow, Bio 101, San Diego, CA) is then added, and the sample is shaken at 37°C for 60 minutes. The sample is then plated on a bacterial growth plate containing bacterial medium and ampicillin at lOOug/ml (Fisher Scientific), and incubated for 16 hours at 37°C.
5. Construct verification
Ten colonies from the ampicillin plate are selected and grown in 1 ml of bacterial medium for 24 hours. One hundred microliters of each culture is stored by adding an equal volume of 50% glycerol solution and frozen at -70°C in mini-tubes. Plasmid DNA is then extracted from the remaining cultures by the mini-prep procedure essentially as described by Maniatis et al. (supra), and the recovered DNAs are analyzed by restriction digest with Xhol and No/I restriction endonucleases. The products of restriction digest are visualized by agarose gel electrophoresis and ethidium bromide staining. Correct plasmids will yield two bands: a vector band of approximately 3 kilobases, and an insert fragment of 1009 bases.
The frozen stock of a colony containing the correct plasmid is used to inoculate one liter of bacterial growth medium containing ampicillin (lOOug ml). The culture is shaken at 37°C for 24 hours, and plasmid DΝA is isolated by a maxi-prep procedure (Promega). The portion on this plasmid coding for soluble human IL-l type 3 receptor is analyzed by DΝA sequencing (US Biochemical) in order to verify that the sequence is correct. B. Transfection Procedure and Expression
COS-7 (ATCC No. CRL 1651) or L-tk" cells (ATCC No. CCL 1.3 ) are seeded at lxlO6 or 3xl06 cells on 10 cm tissue culture dishes and incubated over night. Cells are then transfected by a standard DEAE dextran method. Briefly, lOμg of IL-l type 3 receptor expression plasmid DNA are diluted in 3 ml of Dulbecco's modified Minimum Essential Medium (D-MEM) supplemented with glutamine, pyruvate, 25mM HEPES, 100 microgram/ml DEAE dextran (0.5 Md., Sigma, St. Louis) and 0.1 mM chloroquine (Sigma). Cells are incubated in this transfection mixture for 4 hours at 37°C. After one washing step with D-MEM cells are incubated for 48 hours in D-MEM supplemented with 10% fetal calf serum. At this stage cells are ready for further analysis of the expressed IL-l type 3 receptor.
EXAMPLE 4
SIGNALING OF IL-l VIA THE IL-l TYPE 3 RECEPTOR IN Λ FUNCTIONAL ASSAY
IL-l type 1 receptor cDNA and type 3 receptor cDNA are separately transfected into Jurkat cells (ATCC no. TIB 152) together with a reporter plasmid consisting of the HIV promoter region (HIV-LTR) linked to the bacterial chloramphenicol acetyltransferase (CAT) gene. Stimulation of the transfected cells with human IL-l alpha leads through a signaling cascade involving the transcription factor NF-kappaB to the production of CAT, which in turn can be measured by commercially available assays (Promega, Madison, WI) (see also Leung et al., J. Biol. Chem. 269:1579-1582, 1994).
Results are shown in Figure 3. Briefly, approximately equal stimulation of CAT activity for both receptors can be seen over mock transfected control cells. This indicates that human IL-l alpha can signal through the IL-l type 3 receptor.
EXAMPLE 5
EXPRESSION, LOCALIZATION, AND ACTIVITY OF THE IL-l TYPE 3 RECEPTOR
A. Expression Pattern of the IL-l Type 3 Receptor
In order to determine in which rat tissues and parts of the rat brain the EL-1 Type 3 receptor is expressed, RNA protection assays are performed. Briefly, total 32 RNA is isolated from each tissue or part of the brain and annealed at 65°C to P- labeled RNA generated from a plasmid containing a 600 bp fragment which covers the entire transmembrane region and portions of the extracellular and intracellular domains of the Type 3 receptor cDNA. Samples are then digested with RNase and fractionated on a denaturing polyacrylamice gel. The gel is then dried and the radioactivity quantitated using a Phospholmager (Figure 4).
As can be seen in Figure 4, the highest level of expression is in the lung, followed by the epididymus and testis. When various areas of the brain are examined, the cerebral cortex contains the highest level of the Type 3 receptor, although other areas of the brain were also positive.
B. Localization of the IL-l Type 3 Receptor by In Situ Hybridization
Utilizing in situ hybridization histochemistry, the IL-l type 3 receptor may be found in the thymus and the spleen. In the thymus the signal is most prominent in the cortical region and not in the medulla. Within the rat brain the IL-l type 3 receptor expression is detectable in the hippocampus and the fourth ventricle. This is in contrast to the localization of the IL-l type 1 receptor which is restricted to the dentate gyrus granule cells. Briefly, dissected tissue is frozen in isopentane cooled to -42°C and subsequently stored at -80°C prior to sectioning on a cryostat. Slide-mounted tissue sections are then stored at -80°C. Sections are removed from storage and placed directly into 4% buffered paraformaldehyde at room temperature. After 60 minutes, slides are rinsed in isotonic phosphate buffered saline (10 min.) and treated with proteinase K (1 μg/ml in 100 mM Tris/HCl, pH 8.0) for 10 minutes at 37°C. Subsequently, sections are successively washed in water (1 min.), 0.1 M triethanolamine (pH 8.0, plus 0.25% acetic anhydride) for 10 minutes and 2X SSC (0.3 mM NaCl, 0.03 mM sodium citrate, pH 7.2) for 5 minutes. Sections are then dehydrated through graded alcohols and air dried. Post-fixed sections are hybridized with 1.0 x IO6 dpm [35S]UTP-labeled riboprobes in hybridization buffer containing 75% formamide, 10% dextran sulphate, 3X SSC, 50 mM sodium phosphate buffer pH 7.4), IX Denhardt's solution, 0.1 mg/ml yeast tRNA and 10 mM dithiothreitol in a total volume of 30 μl. The diluted probe is applied to sections on a glass coverslip and hybridized overnight at 55°C in a humid environment. Post-hybridization, sections are washed in 2X SSC for 5 minutes and then treated with RNase A (200 μg/ml in lO mM Tris/HCl, pH 8.0, containing 0.5 M NaCl) for 60 minutes at 37°C. Subsequently, sections are washed in 2X SSC for 5 minutes, IX SSC for 5 minutes, 0.1X SSC for 60 minutes at 70°C, 0.5X SSC at room temperature for 5 minutes and then dehydrated in graded alcohols and air dried. For signal detection, sections are placed on Kodak Bio Max X-ray film and exposed for the required length of time or dipped in photographic emulsion (Amsersham LM-1) for high resolution analysis. Autoradiograms are analyzed using automated image analysis (DAGE camera/Mac II) while dipped sections were examined using a Zeiss Axioscope.
C. Inhibition of Thymocyte Proliferation by the IL-l Type 3 Receptor Ability of the IL-l type 3 receptor to inhibit mouse thymocyte proliferation may also be examined. Briefly, the proliferative response of T lymphocyte lectins such as phytohemagglutin (PHA) is very low, but is markedly enhanced by IL-l . Thus, soluble type human and rat type 3 receptors may be utilized to competitively inhibit proliferation of mouse thymocytes stimulated by IL-l . Soluble human Type 1 receptor produced in baculovirus may be used as a positive control.
Briefly, soluble IL-l type 1 or type 3 receptors are added to wells of a 96 well plate and serially diluted IL-l is also added. Thymi are removed from young mice and a single cell suspension prepared in tissue culture media. Cells are washed 3 times and resuspended at a concentration of 107 cells/ml. Cells are plated at 100 microliters in a 96 well flat bottom microtiter plate. PHA is added to stimulate the cells. Plates are then incubated for 48 hours in a 37°C, 5% CO2 humidified incubator, and [3H] thymidine is added to the cells for the last 4 to 6 hours. Cells are then harvested and the [3H] thymidine incoφoration determined by liquid scintillation counting.
As shown in Figure 5, both human IL-l type 3 and rat IL-l type 3 receptors effectively inhibit thymocyte proliferation in a manner similar to that observed for soluble human type 1 receptor. This result strongly indicates that the type 3 receptor inhibits thymocyte proliferation by binding to the exogenously added IL-l.
From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for puφoses of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims. SEQUENCE LISTING
(1) GENERAL INFORMATION:
(1) APPLICANTS: Lovenberg, Timothy W. Oltersdorf, Tilman LIaw. Chen W. Clevenger, William DeSouza, Errol B.
(ID TITLE OF INVENTION: INTERLEUKIN-1 TYPE 3 RECEPTORS
(ill) NUMBER OF SEQUENCES: 9
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Seed and Berry
(B) STREET: 6300 Columbia Center. 701 Fifth Avenue
(C) CITY: Seattle
(D) STATE: Washington
(E) COUNTRY: US
(F) ZIP: 98104
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentin Release #1.0. Version #1.25
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: McMasters. David D.
(B) REGISTRATION NUMBER: 33.963 (C) REFERENCE/DOCKET NUMBER: 690068.402PC
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (206) 622-4900
(B) TELEFAX: (206) 682-6031
(C) TELEX: 3723836
(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1965 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 129..1814
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:
CGCCCGCCCA CGGCGGCGGG GAAATACCTA GGCATGGAAG TGGCATGACA GGGCTCGTGT 60
CCCTGTCATA TTTTCCACTC TCCACGAGGT CCTGCGCGCT TCAATCCTGC AGGCAGCCCG 120
GTTTGGGG ATG TGG TCC TTG CTG CTC TGC GGG HG TCC ATC GCC CTT CCA 170 Met Trp Ser Leu Leu Leu Cys Gly Leu Ser He Ala Leu Pro 1 5 10
CTG TCT GTC ACA GCA GAT GGA TGC AAG GAC ATT TTT ATG AAA AAT GAG 218 Leu Ser Val Thr Ala Asp Gly Cys Lys Asp He Phe Met Lys Asn Glu 15 20 25 30
ATA CTT TCA GCA AGC CAG CCT TTT GCT TTT AAT TGT ACA TTC CCT CCC 266 He Leu Ser Ala Ser Gin Pro Phe Ala Phe Asn Cys Thr Phe Pro Pro 35 40 45
ATA ACA TCT GGG GAA GTC AGT GTA ACA TGG TAT AAA AAT TCT AGC AAA 314 He Thr Ser Gly Glu Val Ser Val Thr Trp Tyr Lys Asn Ser Ser Lys 50 55 60
ATC CCA GTG TCC AAA ATC ATA CAG TCT AGA Aπ CAC CAG GAC GAG ACT 362 H e Pro Val Ser Lys H e H e Gi n Ser Arg H e Hi s Gi n Asp Gl u Thr 65 70 75
TGG ATT TTG TTT CTC CCC ATG GAA TGG GGG GAC TCA GGA GTC TAC CAA 410 Trp He Leu Phe Leu Pro Met Glu Trp Gly Asp Ser Gly Val Tyr Gin 80 85 90
TGT GTT ATA AAG GGT AGA GAC AGC TGT CAT AGA ATA CAT GTA AAC CTA 458
Cys Val He Lys Gly Arg Asp Ser Cys His Arg He His Val Asn Leu
95 100 105 110
ACT GTT TTT GAA AAA CAT TGG TGT GAC ACT TCC ATA GGT GGT TTA CCA 506 Thr Val Phe Glu Lys His Trp Cys Asp Thr Ser He Gly Gly Leu Pro 115 120 125
AAT TTA TCA GAT GAG TAC AAG CAA ATA TTA CAT CTT GGA AAA GAT GAT 554 Asn Leu Ser Asp Glu Tyr Lys Gin He Leu His Leu Gly Lys Asp Asp 130 135 140
AGT CTC ACA TGT CAT CTG CAC TTC CCG AAG AGT TGT GTT TTG GGT CCA 602 Ser Leu Thr Cys His Leu His Phe Pro Lys Ser Cys Val Leu Gly Pro 145 150 155
ATA AAG TGG TAT AAG GAC TGT AAC GAG ATT AAA GGG GAG CGG TTC ACT 650 He Lys Trp Tyr Lys Asp Cys Asn Glu He Lys Gly Glu Arg Phe Thr 160 165 170
GTT TTG GAA ACC AGG CTT TTG GTG AGC AAT GTC TCG GCA GAG GAC AGA 698 Val Leu Glu Thr Arg Leu Leu Val Ser Asn Val Ser Ala Glu Asp Arg 175 180 185 190
GGG AAC TAC GCG TGT CAA GCC ATA CTG ACA CAC TCA GGG AAG CAG TAC 746 Gly Asn Tyr Ala Cys Gin Ala He Leu Thr His Ser Gly Lys Gin Tyr 195 200 205
GAG GTT TTA AAT GGC ATC ACT GTG AGC ATT ACA GAA AGA GCT GGA TAT 794 Glu Val Leu Asn Gly He Thr Val Ser He Thr Glu Arg Ala Gly Tyr 210 215 220
GGA GGA AGT GTC CCT AAA ATC ATT TAT CCA AAA AAT CAT TCA ATT GAA 842 Gly Gly Ser Val Pro Lys He He Tyr Pro Lys Asn His Ser He Glu 225 230 235
GTA CAG CTT GGT ACC ACT CTG ATT GTG GAC TGC AAT GTA ACA GAC ACC 890 Val Gin Leu Gly Thr Thr Leu He Val Asp Cys Asn Val Thr Asp Thr 240 245 250
AAG GAT AAT ACA AAT CTA CGA TGC TGG AGA GTC AAT AAC ACT TTG GTG 938 Lys Asp Asn Thr Asn Leu Arg Cys Trp Arg Val Asn Asn Thr Leu Val 255 260 265 270
GAT GAT TAC TAT GAT GAA TCC AAA CGA ATC AGA GAA GGG GTG GAA ACC 986 Asp Asp Tyr Tyr Asp Glu Ser Lys Arg He Arg Glu Gly Val Glu Thr 275 280 285
CAT GTC TCT TTT CGG GAA CAT AAT TTG TAC ACA GTA AAC ATC ACC TTC 1034 His Val Ser Phe Arg Glu His Asn Leu Tyr Thr Val Asn He Thr Phe 290 295 300
TTG GAA GTG AAA ATG GAA GAT TAT GGC CTT CCT TTC ATG TGC CAC GCT 1082 Leu Glu Val Lys Met Glu Asp Tyr Gly Leu Pro Phe Met Cys His Ala 305 310 315
GGA GTG TCC ACA GCA TAC ATT ATA TTA CAG CTC CCA GCT CCG GAT TTT 1130 Gly Val Ser Thr Ala Tyr He He Leu Gin Leu Pro Ala Pro Asp Phe 320 325 330 CGA GCT TAC TTG ATA GGA GGG CTT ATC GCC TTG GTG GCT GTG GCT GTG 1178 Arg Ala Tyr Leu He Gly Gly Leu He Ala Leu Val Ala Val Ala Val 335 340 345 350
TCT GTT GTG TAC ATA TAC AAC ATT TTT AAG ATC GAC ATT GTT CTT TGG 1226 Ser Val Val Tyr He Tyr Asn He Phe Lys He Asp He Val Leu Trp 355 360 365
TAT CGA AGT GCC TTC CAT TCT ACA GAG ACC ATA GTA GAT GGG AAG CTG 1274 Tyr Arg Ser Ala Phe His Ser Thr Glu Thr He Val Asp Gly Lys Leu 370 375 380
TAT GAC GCC TAT GTC TTA TAC CCC AAG CCC CAC AAG GAA AGC CAG AGG 1322 Tyr Asp Ala Tyr Val Leu Tyr Pro Lys Pro His Lys Glu Ser Gin Arg 385 390 395
CAT GCC GTG GAT GCC CTG GTG TTG AAT ATC CTG CCC GAG GTG TTG GAG 1370 His Ala Val Asp Ala Leu Val Leu Asn He Leu Pro Glu Val Leu Glu 400 405 410
AGA CAA TGT GGA TAT AAG TTG TTT ATA TTC GGC AGA GAT GAA TTC CCT 1418 Arg Gin Cys Gly Tyr Lys Leu Phe He Phe Gly Arg Asp Glu Phe Pro 415 420 425 430
GGA CAA GCC GTG GCC AAT GTC ATC GAT GAA AAC GTT AAG CTG TGC AGG 1466 Gly Gin Ala Val Ala Asn Val He Asp Glu Asn Val Lys Leu Cys Arg 435 440 445
AGG CTG ATT GTC ATT GTG GTC CCC GAA TCG CTG GGC TTT GGC CTG TTG 1514 Arg Leu He Val He Val Val Pro Glu Ser Leu Gly Phe Gly Leu Leu 450 455 460
AAG AAC CTG TCA GAA GAA CAA ATC GCG GTC TAC AGT GCC CTG ATC CAG 1562 Lys Asn Leu Ser Glu Glu Gin He Ala Val Tyr Ser Ala Leu He Gin 465 470 475 GAC GGG ATG AAG GTT ATT CTC ATT GAG CTG GAG AAA ATC GAG GAC TAC 1610 Asp Gly Met Lys Val He Leu He Glu Leu Glu Lys He Glu Asp Tyr 480 485 490
ACA GTC ATG CCA GAG TCA ATT CAG TAC ATC AAA CAG AAG CAT GGT GCC 1658 Thr Val Met Pro Glu Ser He Gin Tyr He Lys Gin Lys His Gly Ala 495 500 505 510
ATC CGG TGG CAT GGG GAC TTC ACG GAG CAG TCA CAG TGT ATG AAG ACC 1706 He Arg Trp His Gly Asp Phe Thr Glu Gin Ser Gin Cys Met Lys Thr 515 520 525
AAG TTT TGG AAG ACA GTG AGA TAC CAC ATG CCG CCC AGA AGG TGT CGG 1754 Lys Phe Trp Lys Thr Val Arg Tyr His Met Pro Pro Arg Arg Cys Arg 530 535 540
CCG TTT CTC CGG TCC ACG TGC CGC AGC ACA CAC CTC TGT ACC GCA CCG 1802 Pro Phe Leu Arg Ser Thr Cys Arg Ser Thr His Leu Cys Thr Ala Pro 545 550 555
CAG GCC CAG AAC TAGGCTCAAG AAGAAAGAAG TGTACTCTCA CGACTGGCTA 1854 Gin Ala Gin Asn 560
AGACTTGCTG GACTGACACC TATGGCTGGA AGATGACTTG TTTTGCTCCA TGTCTCCTCA 1914
πCCTACACC TATTTTCTGC TGCAGGATGA GGCTAGGGTT AGCATTCTAG A 1965
(2) INFORMATION FOR SEQ ID N0:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 562 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
Met Trp Ser Leu Leu Leu Cys Gly Leu Ser He Ala Leu Pro Leu Ser 1 5 10 15
Val Thr Ala Asp Gly Cys Lys Asp He Phe Met Lys Asn Glu He Leu 20 25 30
Ser Ala Ser Gin Pro Phe Ala Phe Asn Cys Thr Phe Pro Pro He Thr 35 40 45
Ser Gly Glu Val Ser Val Thr Trp Tyr Lys Asn Ser Ser Lys He Pro 50 55 60
Val Ser Lys He He Gin Ser Arg He His Gin Asp Glu Thr Trp He 65 70 75 80
Leu Phe Leu Pro Met Glu Trp Gly Asp Ser Gly Val Tyr Gin Cys Val 85 90 95
He Lys Gly Arg Asp Ser Cys His Arg He His Val Asn Leu Thr Val 100 105 110
Phe Glu Lys His Trp Cys Asp Thr Ser He Gly Gly Leu Pro Asn Leu 115 120 125
Ser Asp Glu Tyr Lys Gin He Leu His Leu Gly Lys Asp Asp Ser Leu 130 135 140
Thr Cys His Leu His Phe Pro Lys Ser Cys Val Leu Gly Pro He Lys 145 150 155 160
Trp Tyr Lys Asp Cys Asn Glu He Lys Gly Glu Arg Phe Thr Val Leu 165 170 175
Glu Thr Arg Leu Leu Val Ser Asn Val Ser Ala Glu Asp Arg Gly Asn 180 185 190
Tyr Ala Cys Gin Ala He Leu Thr His Ser Gly Lys Gin Tyr Glu Val 195 200 205
Leu Asn Gly He Thr Val Ser He Thr Glu Arg Ala Gly Tyr Gly Gly 210 215 220
Ser Val Pro Lys He He Tyr Pro Lys Asn His Ser He Glu Val Gin 225 230 235 240
Leu Gly Thr Thr Leu He Val Asp Cys Asn Val Thr Asp Thr Lys Asp 245 250 255
Asn Thr Asn Leu Arg Cys Trp Arg Val Asn Asn Thr Leu Val Asp Asp 260 265 270
Tyr Tyr Asp Glu Ser Lys Arg He Arg Glu Gly Val Glu Thr His Val 275 280 285
Ser Phe Arg Glu His Asn Leu Tyr Thr Val Asn He Thr Phe Leu Glu 290 295 300
Val Lys Met Glu Asp Tyr Gly Leu Pro Phe Met Cys His Ala Gly Val 305 310 315 320
Ser Thr Ala Tyr He He Leu Gin Leu Pro Ala Pro Asp Phe Arg Ala 325 330 335
Tyr Leu He Gly Gly Leu He Ala Leu Val Ala Val Ala Val Ser Val 340 345 350
Val Tyr He Tyr Asn He Phe Lys He Asp He Val Leu Trp Tyr Arg 355 360 365
Ser Ala Phe His Ser Thr Glu Thr He Val Asp Gly Lys Leu Tyr Asp 370 375 380 Ala Tyr Val Leu Tyr Pro Lys Pro His Lys Glu Ser Gin Arg His Ala 385 390 395 400
Val Asp Ala Leu Val Leu Asn He Leu Pro Glu Val Leu Glu Arg Gin 405 410 415
Cys Gly Tyr Lys Leu Phe He Phe Gly Arg Asp Glu Phe Pro Gly Gin 420 425 430
Ala Val Ala Asn Val He Asp Glu Asn Val Lys Leu Cys Arg Arg Leu 435 440 445
He Val He Val Val Pro Glu Ser Leu Gly Phe Gly Leu Leu Lys Asn 450 455 460
Leu Ser Glu Glu Gin He Ala Val Tyr Ser Ala Leu He Gin Asp Gly 465 470 475 480
Met Lys Val He Leu He Glu Leu Glu Lys He Glu Asp Tyr Thr Val 485 490 495
Met Pro Glu Ser He Gin Tyr He Lys Gin Lys His Gly Ala He Arg 500 505 510
Trp His Gly Asp Phe Thr Glu Gin Ser Gin Cys Met Lys Thr Lys Phe 515 520 525
Trp Lys Thr Val Arg Tyr His Met Pro Pro Arg Arg Cys Arg Pro Phe 530 535 540
Leu Arg Ser Thr Cys Arg Ser Thr His Leu Cys Thr Ala Pro Gin Ala 545 550 555 560
Gin Asn (2) INFORMATION FOR SEQ ID N0:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2044 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 89..1771
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:3:
CCGGCTGGCC TAGGATCAGG CAAGAAAAGG CTGAACGCCT TTCTAAGGAC GGACTCTTTC 60
TGTACAGCTC CACTTGGGGA AGCCCGAA ATG GGG ATG CCA CCC TTG CTC TTC 112
Met Gly Met Pro Pro Leu Leu Phe 1 5
TGT TGG GTG TCT TTC GTG CTT CCA CTT TTT GTG GCA GCA GGT AAC TGT 160 Cys Trp Val Ser Phe Val Leu Pro Leu Phe Val Ala Ala Gly Asn Cys 10 15 20
ACT GAT GTC TAT ATG CAC CAT GAG ATG Aπ TCA GAG GGC CAG CCT TTC 208 Thr Asp Val Tyr Met His His Glu Met He Ser Glu Gly Gin Pro Phe 25 30 35 40
CCC TTC AAC TGC ACA TAC CCT CCA GTA ACA AAC GGG GCA GTG AAT CTG 256 Pro Phe Asn Cys Thr Tyr Pro Pro Val Thr Asn Gly Ala Val Asn Leu 45 50 55
ACA TGG CAT AGA ACA CCC AGT AAG AGC CCA ATC TCC ATC AAC AGA CAC 304 Thr Trp His Arg Thr Pro Ser Lys Ser Pro He Ser He Asn Arg His 60 65 70 GTT AGA Aπ CAC CAG GAC CAG TCC TGG ATT TTG TTT CTT CCG TTG GCA 352 Val Arg He His Gin Asp Gin Ser Trp He Leu Phe Leu Pro Leu Ala 75 80 85
TTG GAG GAC TCA GGC ATC TAT CAA TGT GTT ATA AAG GAT GCC CAC AGC 400 Leu Gl u Asp Ser Gly H e Tyr Gi n Cys Val H e Lys Asp Al a Hi s Ser 90 95 100
TGT TAC CGA ATA GCT ATA AAC CTA ACC GTT TTT AGA AAA CAC TGG TGC 448 Cys Tyr Arg He Ala He Asn Leu Thr Val Phe Arg Lys His Trp Cys 105 110 115 120
GAC TCT TCC AAC GAA GAG AGT TCC ATA AAT TCC TCA GAT GAG TAC CAG 496 Asp Ser Ser Asn Glu Glu Ser Ser He Asn Ser Ser Asp Glu Tyr Gin 125 130 135
CAA TGG TTA CCC ATA GGA AAA TCG GGC AGT CTG ACG TGC CAT CTC TAC 544 Gin Trp Leu Pro He Gly Lys Ser Gly Ser Leu Thr Cys His Leu Tyr 140 145 150
TTC CCA GAG AGC TGT GTT TTG GAT TCA ATA AAG TGG TAT AAG GGT TGT 592 Phe Pro Glu Ser Cys Val Leu Asp Ser He Lys Trp Tyr Lys Gly Cys 155 160 165
GAA GAG Aπ AAA GTG AGC AAG AAG TTT TGC CCT ACA GGA ACA AAG Cπ 640 Glu Glu He Lys Val Ser Lys Lys Phe Cys Pro Thr Gly Thr Lys Leu 170 175 180
CTT Gπ AAC AAC ATC GAC GTG GAG GAT AGT GGG AGC TAT GCA TGC TCA 688 Leu Val Asn Asn He Asp Val Glu Asp Ser Gly Ser Tyr Ala Cys Ser 185 190 195 200
GCC AGA CTG ACA CAC TTG GGG AGA ATC πC ACG GTT AGA AAC TAC Aπ 736 Ala Arg Leu Thr His Leu Gly Arg He Phe Thr Val Arg Asn Tyr He 205 210 215 GCT GTG AAT ACC AAG GAA GTT GGG TCT GGA GGA AGG ATC CCT AAC ATC 784 Al a Val Asn Thr Lys Gl u Val Gly Ser Gly Gly Arg H e Pro Asn H e 220 225 230
ACG TAT CCA AAA AAC AAC TCC ATT GAA GTT CAA Cπ GGC TCC ACC CTC 832 Thr Tyr Pro Lys Asn Asn Ser He Glu Val Gin Leu Gly Ser Thr Leu 235 240 245
ATT GTG GAC TGC AAT ATA ACA GAC ACG AAG GAG AAT ACG AAC CTC AGA 880 He Val Asp Cys Asn He Thr Asp Thr Lys Glu Asn Thr Asn Leu Arg 250 255 260
TGC TGG CGA GTT AAC AAC ACC CTG GTG GAC GAT TAC TAC AAC GAC TTC 928 Cys Trp Arg Val Asn Asn Thr Leu Val Asp Asp Tyr Tyr Asn Asp Phe 265 270 275 280
AAA CGC ATC CAG GAA GGA ATC GAA ACC AAT CTG TCT CTG AGG AAT CAC 976 Lys Arg He Gin Glu Gly He Glu Thr Asn Leu Ser Leu Arg Asn His 285 290 295
ATT CTG TAC ACA GTG AAC ATA ACA TTC TTA GAA GTG AAA ATG GAG GAC 1024 He Leu Tyr Thr Val Asn He Thr Phe Leu Glu Val Lys Met Glu Asp 300 305 310
TAC GGC CAT CCT TTC ACA TGC CAC GCT GCG GTG TCC GCA GCC TAC ATC 1072 Tyr Gly Hi s Pro Phe Thr Cys Hi s Al a Al a Val Ser Al a Al a Tyr H e 315 320 325
Aπ CTG AAA CGC CCA GCT CCA GAC πC CGG GCT TAC CTC ATA GGA GGT 1120 He Leu Lys Arg Pro Ala Pro Asp Phe Arg Ala Tyr Leu He Gly Gly 330 335 340
CTC ATG GCT πC CTA CTT CTG GCC GTG TCC ATT CTG TAC ATC TAC AAC 1168 Leu Met Ala Phe Leu Leu Leu Ala Val Ser He Leu Tyr He Tyr Asn 345 350 355 360
ACC πT AAG GTC GAC ATC GTG Cπ TGG TAT AGG AGT ACC TTC CAC ACT 1216 Thr Phe Lys Val Asp He Val Leu Trp Tyr Arg Ser Thr Phe His Thr 365 370 375
GCC CAG GCT CCA GAT GAC GAG AAG CTG TAT GAT GCC TAT GTC TTA TAC 1264 Ala Gin Ala Pro Asp Asp Glu Lys Leu Tyr Asp Ala Tyr Val Leu Tyr 380 385 390
CCC AAG TAC CCA AGA GAA AGC CAG GGC CAT GAT GTG GAC ACA CTG GTG 1312 Pro Lys Tyr Pro Arg Glu Ser Gin Gly His Asp Val Asp Thr Leu Val 395 400 405
TTG AAG ATC TTG CCC GAG GTG CTG GAG AAA CAG TGT GGA TAT AAG TTA 1360 Leu Lys He Leu Pro Glu Val Leu Glu Lys Gin Cys Gly Tyr Lys Leu 410 415 420
TTC ATA πT GGC AGG GAT GAA TTC CCT GGA CAA GCT GTG GCC AGC GTC 1408 Phe He Phe Gly Arg Asp Glu Phe Pro Gly Gin Ala Val Ala Ser Val 425 430 435 440
ATT GAT GAA AAC ATT AAG CTG TGT AGG AGG CTG ATG GTC CTC GTG GCA 1456 He Asp Glu Asn He Lys Leu Cys Arg Arg Leu Met Val Leu Val Ala 445 450 455
CCA GAG ACA TCC AGC TTC AGC TTT CTG AAG AAC TTG ACT GAA GAA CAA 1504 Pro Glu Thr Ser Ser Phe Ser Phe Leu Lys Asn Leu Thr Glu Glu Gin 460 465 470
ATC GCT GTC TAC AAT GCC CTC GTC CAG GAC GGC ATG AAG GTC ATT CTG 1552 He Ala Val Tyr Asn Ala Leu Val Gin Asp Gly Met Lys Val He Leu 475 480 485
ATT GAA CTG GAG AGA GTC AAG GAC TAC AGC ACC ATG CCC GAG TCC Aπ 1600 He Glu Leu Glu Arg Val Lys Asp Tyr Ser Thr Met Pro Glu Ser He 490 495 500
CAG TAC ATC CGA CAG AAG CAC GGG GCC ATC CAG TGG GAT GGG GAC TTC 1648 Gin Tyr He Arg Gin Lys His Gly Ala He Gin Trp Asp Gly Asp Phe 505 510 515 520
ACA GAG CAG GCA CAG TGC GCC AAG ACG AAA πC TGG AAG AAA GTG AGA 1696 Thr Glu Gin Ala Gin Cys Ala Lys Thr Lys Phe Trp Lys Lys Val Arg 525 530 535
TAT CAT ATG CCA CCC AGG AGG TAC CCG GCA TCT CCC CCC GTC CAG CTG 1744 Tyr His Met Pro Pro Arg Arg Tyr Pro Ala Ser Pro Pro Val Gin Leu 540 545 550
CTA GGA CAC ACA CCC CGC ATA CCA GGC TAGTGCAGTG CCACCGCCAC 1791 Leu Gly His Thr Pro Arg He Pro Gly 555 560
GGGGCTCATA ACTCCTTAAG AGCGGTTAGT GTGTGGTGGC TCGCACTACA ACCTCTCTGG 1851
ATCATCTACC CCCGTAGCTT GCTCTTTTGT GCTTGTGAGC GACCTCGTCC TTAGCCACGT 1911
CATATTTTGA TTTTTTGTTT GTTTTGTTTG TTTGTTGTAT GCTTTTAGTC ATAGCTGATT 1971
CGTACTACTC CTGTTTGCTT CATGGTTCCT GAATCCCAGA GACTCCCTGA GCATGGGTGG 2031
CTATCATGTT GGG 2044
(2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 561 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
Met Gly Met Pro Pro Leu Leu Phe Cys Trp Val Ser Phe Val Leu Pro 1 10 15
Leu Phe Val Ala Ala Gly Asn Cys Thr Asp Val Tyr Met His His Glu 20 25 30
Met He Ser Glu Gly Gin Pro Phe Pro Phe Asn Cys Thr Tyr Pro Pro 35 40 45
Val Thr Asn Gly Ala Val Asn Leu Thr Trp His Arg Thr Pro Ser Lys 50 55 60
Ser Pro He Ser He Asn Arg His Val Arg He His Gin Asp Gin Ser 65 70 75 80
Trp He Leu Phe Leu Pro Leu Ala Leu Glu Asp Ser Gly He Tyr Gin 85 90 95
Cys Val He Lys Asp Ala His Ser Cys Tyr Arg He Ala He Asn Leu 100 105 110
Thr Val Phe Arg Lys His Trp Cys Asp Ser Ser Asn Glu Glu Ser Ser 115 120 125
He Asn Ser Ser Asp Glu Tyr Gin Gin Trp Leu Pro He Gly Lys Ser 130 135 140
Gly Ser Leu Thr Cys His Leu Tyr Phe Pro Glu Ser Cys Val Leu Asp 145 150 155 160
Ser He Lys Trp Tyr Lys Gly Cys Glu Glu He Lys Val Ser Lys Lys 165 170 175
Phe Cys Pro Thr Gly Thr Lys Leu Leu Val Asn Asn He Asp Val Glu 180 185 190
Asp Ser Gly Ser Tyr Ala Cys Ser Ala Arg Leu Thr His Leu Gly Arg 195 200 205 He Phe Thr Val Arg Asn Tyr He Ala Val Asn Thr Lys Glu Val Gly 210 215 220
Ser Gly Gly Arg He Pro Asn He Thr Tyr Pro Lys Asn Asn Ser He 225 230 235 240
Glu Val Gin Leu Gly Ser Thr Leu He Val Asp Cys Asn He Thr Asp 245 250 255
Thr Lys Glu Asn Thr Asn Leu Arg Cys Trp Arg Val Asn Asn Thr Leu 260 265 270
Val Asp Asp Tyr Tyr Asn Asp Phe Lys Arg He Gin Glu Gly He Glu 275 280 285
Thr Asn Leu Ser Leu Arg Asn His He Leu Tyr Thr Val Asn He Thr 290 295 300
Phe Leu Glu Val Lys Met Glu Asp Tyr Gly His Pro Phe Thr Cys His 305 310 315 320
Ala Ala Val Ser Ala Ala Tyr He He Leu Lys Arg Pro Ala Pro Asp 325 330 335
Phe Arg Ala Tyr Leu He Gly Gly Leu Met Ala Phe Leu Leu Leu Ala 340 345 350
Val Ser He Leu Tyr He Tyr Asn Thr Phe Lys Val Asp He Val Leu 355 360 365
Trp Tyr Arg Ser Thr Phe His Thr Ala Gin Ala Pro Asp Asp Glu Lys 370 375 380
Leu Tyr Asp Ala Tyr Val Leu Tyr Pro Lys Tyr Pro Arg Glu Ser Gin 385 390 395 400 Gly His Asp Val Asp Thr Leu Val Leu Lys He Leu Pro Glu Val Leu 405 410 415
Glu Lys Gin Cys Gly Tyr Lys Leu Phe He Phe Gly Arg Asp Glu Phe 420 425 430
Pro Gly Gin Ala Val Ala Ser Val He Asp Glu Asn He Lys Leu Cys 435 440 445
Arg Arg Leu Met Val Leu Val Ala Pro Glu Thr Ser Ser Phe Ser Phe 450 455 460
Leu Lys Asn Leu Thr Glu Glu Gin He Ala Val Tyr Asn Ala Leu Val 465 470 475 480
Gin Asp Gly Met Lys Val He Leu He Glu Leu Glu Arg Val Lys Asp 485 490 495
Tyr Ser Thr Met Pro Glu Ser He Gin Tyr He Arg Gin Lys His Gly 500 505 510
Ala He Gin Trp Asp Gly Asp Phe Thr Glu Gin Ala Gin Cys Ala Lys 515 520 525
Thr Lys Phe Trp Lys Lys Val Arg Tyr His Met Pro Pro Arg Arg Tyr 530 535 540
Pro Ala Ser Pro Pro Val Gin Leu Leu Gly His Thr Pro Arg He Pro 545 550 555 560
Gly
(2) INFORMATION FOR SEQ ID N0:5:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:5:
Asp Tyr Lys Asp Asp Asp Asp Lys 1 5
(2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:
CTTCAACTGC ACATACCCTC CAGTAACAAA CGGGGCAGTG AATCTGACAT 50
(2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
CCTCCCATAA CATCTGGGGA AGTCAGTGTA ACATGGTATA AAAATTCTAG C 51 (2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:
CCTACTCGAG ATGTGGTCCT TGCTGCTC 28
(2) INFORMATION FOR SEQ ID N0:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:9:
ATGCGCGGCC GCCTATCGAA AATCCGGAGC TGG 33

Claims

Claims
1. An isolated nucleic acid molecule encoding an Interleukin- 1 Type 3 receptor.
2. The isolated nucleic acid molecule according to claim 1, comprising the sequence of nucleotides in Sequence I.D. No. 1 , from nucleotide number 129 to nucleotide number 1814.
3. The isolated nucleic acid molecule according to claim 1 wherein said molecule encodes a protein having the amino acid sequence of Sequence I.D. No. 2, from amino acid number 1 to amino acid number 562.
4. The isolated nucleic acid molecule according to claim 1, comprising the sequence of nucleotides in Sequence I.D. No. 3, from nucleotide number 89 to nucleotide number 1771.
5. The isolated nucleic acid molecule according to claim 1 wherein said molecule encodes a protein having the amino acid sequence of Sequence I.D. No. 4, from amino acid number 1 to amino acid number 561.
6. The isolated nucleic acid molecule according to claim 1 wherein said molecule encodes a human Interleukin- 1 Type 3 receptor.
7. The isolated nucleic acid molecule according to claim 1 wherein said molecule encodes a rat Interleukin- 1 Type 3 receptor.
8. An isolated nucleic acid molecule encoding soluble Interleukin- 1 Type 3 receptor.
9. The isolated nucleic acid molecule according to claim 8, comprising the sequence of nucleotides in Sequence I.D. No. 1, from nucleotide number 129 to nucleotide number 1136.
10. The isolated nucleic acid molecule according to claim 8 wherein said molecule encodes a protein having the amino acid sequence of Sequence I.D. No. 2, from amino acid number 1 to amino acid number 336.
11. The isolated nucleic acid molecule according to claim 8, comprising the sequence of nucleotides in Sequence I.D. No. 3, from nucleotide number 89 to nucleotide number 1102.
12. The isolated nucleic acid molecule according to claim 8 wherein said molecule encodes a protein having the amino acid sequence of Sequence I.D. No. 4, from amino acid number 1 to amino acid number 338.
13. The isolated nucleic acid molecule according to claim 8 wherein said molecule encodes a soluble human Interleukin- 1 Type 3 receptor.
14. The isolated nucleic acid molecule according to claim 8 wherein said molecule encodes a soluble rat Interleukin- 1 Type 3 receptor.
15. A recombinant expression vector, comprising a promoter operably linked to a nucleic acid molecule according to any one of claims 1-14.
16. A recombinant viral vector capable of directing the expression of a nucleic acid molecule according to any one of claims 1-14 wherein said vector is selected from the group consisting of retroviral vectors, adenoviral vectors, and heφes simplex virus vectors.
17. A host cell containing a recombinant vector according to any one of claims 15 or 16.
18. An isolated Interleukin- 1 Type 3 receptor.
19. The isolated Interleukin-1 Type 3 receptor according to claim 18 having the amino acid sequence of Sequence I.D. No. 2, from amino acid number 1 to amino acid number 562.
20. The isolated Interleukin- 1 Type 3 receptor according to claim 18 having the amino acid sequence of Sequence I.D. No. 4, from amino acid number 1 to amino acid number 561.
21. The isolated Interleukin- 1 Type 3 receptor according to claim 18 wherein said receptor is a human Interleukin- 1 Type 3 receptor.
22. The isolated Interleukin-1 Type 3 receptor according to claim 18 wherein said receptor is a rat Interleukin- 1 Type 3 receptor.
23. An isolated soluble Interleukin- 1 Type 3 receptor.
24. The isolated soluble Interleukin- 1 Type 3 receptor according to claim 23 having the amino acid sequence of Sequence I.D. No. 2, from amino acid number 1 to amino acid number 336.
25. The isolated soluble Interleukin- 1 Type 3 receptor according to claim 23 having the amino acid sequence of Sequence I.D. No. 4, from amino acid number 1 to amino acid number 338.
26. The isolated soluble Interleukin- 1 Type 3 receptor according to claim 23 wherein said receptor is a human Interleukin- 1 Type 3 receptor.
27. The isolated soluble Interleukin- 1 Type 3 receptor according to claim 23 wherein said receptor is a rat Interleukin- 1 Type 3 receptor.
28. An isolated antibody capable of specifically binding to an Interleukin- 1 Type 3 receptor.
29. The antibody according to claim 28 wherein said antibody is selected from the group consisting of polyclonal antibodies, monoclonal antibodies, and antibody fragments.
30. The antibody according to claim 28 wherein said antibody is capable of blocking the binding of IL-l to an Interleukin- 1 Type 3 receptor.
31. The antibody according to claim 28 wherein said antibody is selected from the group consisting of murine and human antibodies.
32. A hybridoma which produces an antibody according to any one of claims 28-31.
33. A nucleic acid probe of at least 18 nucleotides in length which is capable of specifically hybridizing to a nucleic acid sequence encoding an Interleukin- 1 Type 3 receptor.
PCT/US1995/012037 1994-09-09 1995-09-11 Interleukin-1 type 3 receptors WO1996007739A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95934482A EP0779923A2 (en) 1994-09-09 1995-09-11 Interleukin-1 type 3 receptors
JP8509726A JPH10508743A (en) 1994-09-09 1995-09-11 Interleukin-1 type 3 receptor
AU36805/95A AU705595B2 (en) 1994-09-09 1995-09-11 Interleukin-1 type 3 receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30395794A 1994-09-09 1994-09-09
US08/303,957 1994-09-09

Publications (2)

Publication Number Publication Date
WO1996007739A2 true WO1996007739A2 (en) 1996-03-14
WO1996007739A3 WO1996007739A3 (en) 1996-04-18

Family

ID=23174426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012037 WO1996007739A2 (en) 1994-09-09 1995-09-11 Interleukin-1 type 3 receptors

Country Status (5)

Country Link
EP (1) EP0779923A2 (en)
JP (1) JPH10508743A (en)
AU (1) AU705595B2 (en)
CA (1) CA2199609A1 (en)
WO (1) WO1996007739A2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
WO1999019480A2 (en) * 1997-10-15 1999-04-22 Schering Corporation Human receptor proteins; related reagents and methods
US6057155A (en) * 1995-11-28 2000-05-02 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
WO2001057219A2 (en) * 2000-02-02 2001-08-09 Schering Corporation Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
US6326472B1 (en) 1997-10-15 2001-12-04 Schering Corporation Human receptor proteins; related reagents and methods
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6951755B2 (en) 1994-09-08 2005-10-04 Genvec, Inc. Vectors and methods for gene transfer
US6974695B2 (en) 2000-11-15 2005-12-13 Crucell Holland B.V. Complementing cell lines
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US7749493B2 (en) 1998-07-08 2010-07-06 Crucell Holland B.V. Chimeric adenoviruses
US11267893B2 (en) 2018-07-16 2022-03-08 Regeneron Pharmaceuticals, Inc. Anti-IL36R antibodies

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804028B1 (en) * 2000-01-21 2004-06-04 Merial Sas IMPROVED DNA VACCINES FOR PENSION ANIMALS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019777A1 (en) * 1992-03-30 1993-10-14 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
WO1994020517A1 (en) * 1993-03-08 1994-09-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for treating a connective tissue of a mammalian host
EP0623674A1 (en) * 1987-11-25 1994-11-09 Immunex Corporation Interleukin-1 receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0623674A1 (en) * 1987-11-25 1994-11-09 Immunex Corporation Interleukin-1 receptors
WO1993019777A1 (en) * 1992-03-30 1993-10-14 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
WO1994020517A1 (en) * 1993-03-08 1994-09-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for treating a connective tissue of a mammalian host

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951755B2 (en) 1994-09-08 2005-10-04 Genvec, Inc. Vectors and methods for gene transfer
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6153435A (en) * 1995-02-21 2000-11-28 Cornell Research Foundation, Inc. Nucleic acid that encodes a chimeric adenoviral coat protein
US6649407B2 (en) 1995-11-28 2003-11-18 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6329190B1 (en) 1995-11-28 2001-12-11 Genvec, Inc. Targetting adenovirus with use of constrained peptide motifs
US6057155A (en) * 1995-11-28 2000-05-02 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6326472B1 (en) 1997-10-15 2001-12-04 Schering Corporation Human receptor proteins; related reagents and methods
WO1999019480A3 (en) * 1997-10-15 1999-06-24 Schering Corp Human receptor proteins; related reagents and methods
WO1999019480A2 (en) * 1997-10-15 1999-04-22 Schering Corporation Human receptor proteins; related reagents and methods
US7749493B2 (en) 1998-07-08 2010-07-06 Crucell Holland B.V. Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US7250293B2 (en) 1999-05-18 2007-07-31 Crucell Holland B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7270811B2 (en) 1999-05-18 2007-09-18 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6843987B2 (en) 2000-02-02 2005-01-18 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
WO2001057219A3 (en) * 2000-02-02 2002-03-07 Schering Corp Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
WO2001057219A2 (en) * 2000-02-02 2001-08-09 Schering Corporation Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US6974695B2 (en) 2000-11-15 2005-12-13 Crucell Holland B.V. Complementing cell lines
US7344883B2 (en) 2000-11-15 2008-03-18 Crucell Holland B.V. Complementing cell lines
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US11267893B2 (en) 2018-07-16 2022-03-08 Regeneron Pharmaceuticals, Inc. Anti-IL36R antibodies

Also Published As

Publication number Publication date
CA2199609A1 (en) 1996-03-14
WO1996007739A3 (en) 1996-04-18
JPH10508743A (en) 1998-09-02
EP0779923A2 (en) 1997-06-25
AU705595B2 (en) 1999-05-27
AU3680595A (en) 1996-03-27

Similar Documents

Publication Publication Date Title
CA2124085C (en) Receptor for oncostatin m and leukemia inhibitory factor
AU696775B2 (en) IL-17 receptor
JP4392058B2 (en) Oncostatin M receptor
FI116943B (en) A method for producing tumor necrosis factor receptor fusion proteins encoding DNA and a vector
AU705595B2 (en) Interleukin-1 type 3 receptors
JP3515112B2 (en) Glucagon receptor
IE883523L (en) Interleukin-1 Receptors
CA2241564A1 (en) Wsx receptor and ligands
NZ238255A (en) Type ii interleukin i receptor proteins and their preparation
AU717928B2 (en) Human interleukin-11 receptor
JPH06504438A (en) leukemia inhibitory factor receptor
CA2188279C (en) Interleukin-15 receptors
US7084253B2 (en) Protease-activated receptor PAR4 (ZCHEMR2)
AU703140B2 (en) Corticotropin-releasing factor2 receptors
IE66494B1 (en) Granulocyte-colony stimulating factor receptors
US5776725A (en) Recombinant production of glucagon receptors
CA2123492C (en) Lymphoid antigen cd30
US5786203A (en) Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US6239268B1 (en) Interleukin-1 type 3 receptors
JP3067798B2 (en) Granulocyte colony stimulating factor receptor
US6274547B1 (en) Methods comprising the use of human interleukin-11 receptor proteins
AU625534B2 (en) Interleukin-1 receptors
WO2000071717A1 (en) Secreted alpha-helical protein - 32
IE911108A1 (en) Isolated Viral Protein Cytokine Antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase in:

Ref document number: 2199609

Country of ref document: CA

Ref country code: CA

Ref document number: 2199609

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995934482

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995934482

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995934482

Country of ref document: EP